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 Associations of cardiovascular risk factors, cognitive performance, and 
depressive symptoms have been well established.  However, the directionality of these 
associations as well as the specificity of these associations with respect to executive 
function are less clear.  Additionally few studies have determined whether genetic risk 
factors, such as apolipoprotein-E4 (APOE-E4) genotype, and age moderate the 
associations of cardiovascular risk factors such as homocysteine with changes in 
depressive symptoms and how these associations may be mediated by cognitive 
performance.  The primary aim of this study was to analyze the bidirectional 
associations of a full range of cognitive domains and symptoms of depression over a 
period of 5 years and to determine the extent to which the conditional associations of 
homocysteine (moderated by age and APOE-E4 genotype) and changes in depressive 
symptoms are mediated by cognitive performance.  Additionally, we aimed to determine 
the extent to which these associations are specific to executive function as compared 
  
with other domains of cognitive function.  After exclusions for probable dementia, kidney 
dialysis, and acute stroke, 719 adult participants were available for analysis for the sixth 
and seventh waves of the Maine-Syracuse Longitudinal Study.  We conducted cross-
sectional multiple linear regression analyses and cross-lagged panel analyses (CLPD) 
to determine the strength and directionality of associations for cognitive function and 
symptoms of depression.  Next, we conducted conditional mediation path analyses to 
explore the associations of homocysteine (moderated by age and APOE-E4) and 
changes in self-reported depressive symptoms as mediated by cognitive function.  All 
models were adjusted for wave 6 demographic covariates (age, sex, education, 
ethnicity, and marital status), cardiovascular risk profile (Framingham Risk Score), and 
depressive symptoms.  In fully adjusted cross-sectional models, depressive symptoms 
were inversely associated with executive function and several other cognitive domains.  
In CLPD, cognitive performance was a stronger and more consistent predictor of 
changes in depressive symptoms (Executive Function, Global performance, Scanning 
and Tracking, and Visual-Spatial Organization and Memory) than depressive symptoms 
were of changes in performance.  Although cognitive performance largely did not 
mediate the associations of cardiovascular risk factors (homocysteine and Framingham 
Risk Score) and changes in depressive symptoms, we did observe direct associations 
of Framingham Risk Score and changes in symptoms as well as significant moderation 
by age and APOE-E4 for the associations of homocysteine and changes in depressive 
symptoms.  For APOE-E4 non-carriers, higher homocysteine was associated with 
symptom increases for individuals ≥ 74.33 years of age and for APOE-E4 carriers, there 
were marginal risks for individuals ≤ 45 years of age.  The findings of this study have 
  
important clinical implications in assessing risk for and prevention of depressive 
symptoms both via maintenance of cognitive function and CVD risk reduction. Better 
executive functioning and performance in other cognitive domains was associated with 
lower levels of depressive symptoms over five years. Lower levels of CVD risk, both for 
the well-established CVD risk factors indexed by the Framingham Risk Score and for 
homocysteine, were associated with lower levels of depressive symptoms over five 
years.  Moderation of depressive symptoms may be afforded through interventions 
designed to maintain executive function and to reduce risk relating to modifiable CVD 
risk factors such as homocysteine.  Clinical trials with patient populations are needed to 
determine whether modification of homocysteine via dietary or physical activity 
adjustments could provide effective prevention of depressive symptoms.
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1. INTRODUCTION 
 Human cognitive and emotional development is rapid in early life, but it is well 
known that changes continue to occur throughout adulthood and into later life.  One 
influential cognitive aging model distinguishes between total fund of world knowledge 
(i.e., crystalized), which tends to remain stable in older adulthood and abilities relating to 
speed and power of decision-making (i.e., fluid), which tends to decline with aging 
(Glisky, 2007; Harada, Natelson Love, & Triebel, 2013; Horn & Cattell, 1967).  It is also 
well known that cognition and emotion regulation have considerable overlap at every 
age (Hammar & Ardal, 2009).  Successfully coping with novel events and stressors 
requires both the ability to regulate emotion and the ability to select, plan, initiate, and 
reevaluate appropriate behavioral actions.  However, despite some overlap between 
cognitive ability and depressive symptoms, not all individuals with high levels of 
depressive symptoms have low cognitive ability and not all of those with low cognitive 
ability experience high levels of depressive symptoms, which have led many 
researchers to examine what risk factors may be common to both conditions.  
 Interest continues to grow with regard to the vascular risk factors that are 
common among older individuals with cognitive deficits and depressive symptoms and 
there is an expanding literature on the possibility that vascular mechanisms underlie the 
relationships between cognitive decline and depressive symptoms.  Prevention and 
reduction of vascular risks through lifestyle changes and pharmacological treatment 
may not only reduce the medical burden posed by cognitive decline and symptoms of 
depression, but may also result in a lifespan compression of overall morbidity and 
dependent/institutional living.   
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 In Section 1.1, we review different measurements of depressive symptoms 
(Section 1.1.1), depressive symptoms and aging (Section 1.1.2) and the vascular 
depression hypothesis (Alexopoulos et al., 1997; Section 1.1.3).  In Section 1.2, we 
highlight two vascular risk factors of interest: homocysteine (Section 1.2.1) and 
Apolipoprotein E genotype (Section 1.2.2). 
 In Section 1.3 we discuss the measurement and course of cognitive performance 
and the prevalence of cognitive impairment (Section 1.3.1) and its relationship with 
executive function, vascular disease, and homocysteine (Sections 1.3.2 to 1.3.4).   We 
then discuss how executive function, aging, and symptoms of depression may be 
related (Section 1.4) by summarizing the literature on depression-executive dysfunction 
syndrome (Section 1.4.1) and, possible directional associations of depressive 
symptoms and cognitive performance/executive function.  We close chapter 1 by 
proposing possible mechanisms of cognitive decline (1.4.2 to 1.4.3). 
 In this study, we first aim to expand upon the vascular depression hypothesis by 
observing how performance across several cognitive domains may predict changes in 
depressive symptoms over time.  After exploring the temporal connection between 
cognitive performance and depressive symptoms, we analyze whether cardiovascular 
risk factors such as age, APOE-E4 genotype, and homocysteine interact to predict 
changes in symptoms of depression through their associations with cognitive 
performance. 
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1.1 Symptoms of Depression 
Episodes of major depression are characterized by a wide range of persistent 
affective, behavioral, and cognitive symptoms.  There are two main competing 
diagnostic systems currently in use, the World Health Organization’s International 
Classification of Diseases (ICD-10; WHO, 2016) and the American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-5; APA, 
2013).  Although there is some difference with regard to the specific word choice for 
describing diagnostic criterion, the DSM-5 and the ICD-10 overlap considerably 
regarding the diagnosis of an episode of Major Depressive Disorder (MDD).  
Specifically, MDD is characterized by persistent dysphoria and loss of interest/pleasure 
in daily activities and may include any of the following symptoms: disturbance in 
sleep/weight/appetite/psychomotor activity, fatigue, feelings of guilt/worthlessness, 
diminished ability to concentrate or make decisions, and thoughts of suicide.  In both the 
ICD-10 and DSM-5, individuals with MDD may be further subdivided into Mild, Moderate 
or Severe categories based on symptom count and severity, but they are ultimately 
categorical taxonomies.  These systems provide useful heuristics for binary treatment 
decision-making, but evidence from community-based population studies suggests that 
unipolar depression is more likely to be a dimensional construct with a continuum of 
related symptoms found among all individuals (Prisciandaro & Roberts, 2005).  This is 
important because individuals often experience similar levels of functional impairment 
despite being just below a diagnostic threshold (Prisciandaro & Roberts, 2005).  The 
next section will discuss both the diagnostic prevalence of MDD as well as the 
phenomenology of symptoms of depression in older compared with younger adults. 
   4 
1.1.1 Symptoms of Depression and Aging 
 MDD is one of the most common mental health disorders in the United States.  In 
2014, approximately 15.7 million adults (6.7%) experienced at least one Major 
Depressive Episode (MDE) in the past 12 months.  Compared with younger (9.3%) and 
middle-aged adults (7.2%), older adults (5.2%) are estimated to have a lower 12-month 
prevalence rate of MDE (Center for Behavioral Health Statistics and Quality, 2015).  
However, lower estimates of MDD among older adults may be systematically biased by 
the association between MDD and early mortality (Blazer, 2009).  Additionally, older 
adults (≥ 65y) are less likely to identify a range of symptoms of depression (i.e., 
sadness, guilt, thoughts of suicide, motor slowing, trouble concentrating, and insomnia) 
compared with younger adults (< 65y; Wetherell et al., 2009).  Current diagnostic 
systems also prioritize dysphoria which is less commonly endorsed by older adults 
compared with younger adults (Hegeman et al., 2012). 
 However, despite a general decreasing trend for depressive symptoms in the 
transition from middle to later adulthood, older adults are at an increased risk for 
experiencing a number of conditions associated with depression.  For example, 
symptoms of depression are common among those recovering from myocardial 
infarction, stroke, and hip fractures or suffering from diabetes, arthritis, and kidney 
disease (Blazer, 2009).  Additionally, institutional living, lack of social support, 
bereavement, functional impairment and loss of economic power are also more 
common, especially among the oldest old and contribute a significant level of risk for 
depressive symptoms (Blazer, Burchett, Service, & George, 1991; McDougall, 
Matthews, Kvaal, Dewey, & Brayne, 2007).  Sleep disturbance, subjective memory 
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complaints, fatigue, and motor slowing, which are more common among depressed 
older adults, may be misconstrued as conditions associated with normal aging, 
medication use, or general medical ailments (Fiske, Wetherell, & Gatz, 2009). 
 Although the risk for future depressive episodes is considerably greater for those 
with a history of MDD (Burcusa & Iacono, 2007), as many as half of older adults with 
MDD experience the condition as a first episode (Brodaty et al., 2001).  Most studies 
define “late-onset depression” as experiencing an initial depressive episode after the 
ages of 50 – 65 (Blazer, 2009; Driscoll et al., 2005; Fountoulakis et al., 2003; 
Mahapatra, Sharma, & Khandelwal, 2015).  Evidence suggests that among older adults, 
those with early or late-onset depression exhibit similar levels of severity and diagnostic 
phenotypes; however, late-onset depression appears to be less associated with family 
history of mood disorders and pre-morbid personality abnormalities and more 
associated with recent stressful events (Brodaty et al., 2001; Bukh, Bock, Vinberg, 
Gether, & Kessing, 2011; Burcusa & Iacono, 2007).  This suggests that although the 
phenomenology of early and late-onset depression among older adults may be similar, 
they may result from different etiological factors.  Investigations of these pathways have 
focused on age-related risk factors associated with structural and functional changes in 
the brain among older adults.  
1.1.2 Vascular Depression 
 The vascular depression hypothesis was coined by Alexopoulos et al. (1997), 
following case observations of older adult patients suffering from depression.  They 
proposed that cerebrovascular disease may predispose or exacerbate symptoms of 
depression via disruption of frontostriatal circuits responsible for emotion regulation and 
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executive function (discussed later).  Evidence for the vascular depression hypothesis 
can be found in the high level of observed comorbidity between symptoms of 
depression and vascular disease.  In one analysis, 53% and 42% of patients (N = 106, 
age range 19-82y) were diagnosed with major or minor depression 3 and 6 months 
respectively following an ischemic stroke (Kauhanen et al., 1999), which is the result of 
severe restriction or blockage of cerebral blood flow.  Stroke may be one of the most 
acute vascular events associated with altered brain functioning, but evidence also 
suggests that more silent, but chronic conditions and markers of vascular disease may 
be associated with symptoms of depression in late life among those without history of 
stroke or major vascular event.   
Magnetic resonance imaging (MRI) studies have allowed researchers to observe 
the associations of less severe, but none-the-less damaging small vessel diseases with 
depressive symptoms among older adults.  Several MRI studies of depressed patients 
have shown greater volume of ischemic white matter lesions (shown as white matter 
hyperintensities, WMH) and lower neuronal density compared with age matched 
controls, particularly in the dorsolateral prefrontal cortex, orbitofrontal cortex, and in the 
caudate nucleus (Firbank, Llyod, Ferrier, & O’Brien, 2004; Khundakar, Morris, Oakley, & 
Thomas, 2011; W. D. Taylor et al., 2007; Thomas et al., 2002).  Additionally, after 
adjustment for baseline depressive symptoms and cardiovascular risk factors, WMH 
volume, increases in subcortical infarcts, and decreases in brain volume have predicted 
depressive symptoms severity in 3-5 year prospective analyses among community 
dwelling older adults  (Firbank et al., 2004; Godin et al., 2008; van Sloten et al., 2015).  
Although there is not yet a consensus on whether vascular depression represents a 
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distinct clinical subtype of depression (Sneed & Culang-Reinlieb, 2011), researchers are 
increasingly looking towards the possibility that various vascular risk factors may place 
some individuals at a higher risk for depressive symptoms later in life.   
1.2 Vascular Risk Factors:  Homocysteine and Apolipoprotein Genotype 
 The major vascular risk factors emphasized in this study are homocysteine and 
apolipoprotein genotype.  In the sections that follow, the literature on each will be briefly 
discussed with regard to their vascular risk status and associations with cognitive 
performance and depressive symptoms. 
1.2.1 Homocysteine 
Homocysteine (Hcy) is a sulfur amino acid metabolite biosynthesized from 
ingested methionine found in many dietary proteins.  Methionine, via its conversion to S-
adenosyltransferase is essential in the stabilization of proteins including myelin and is 
also involved in the synthesis of melatonin, norepinephrine, and in the metabolism of 
serotonin.  Normally, in concert with the folate (B9) cycle, Hcy is either converted back 
into methionine by cofactor cobalamin (B12) via re-methylation or converted to cysteine 
and taurine by pyriodoxine (B6) via trans-sulfuration (Ganguly & Alam, 2015; Refsum et 
al., 2004).  Low dietary intake or absorption of B-vitamin cofactors are among the most 
common causes for elevated Hcy, defined as >15 µmol/L for adults aged 15-65 years of 
age (>12 µmol/L folic acid supplemented) and >20 µmol/L for adults >65 years of age 
(>16 µmol/L folic acid supplemented; Refsum et al., 2004).  In addition to age, male 
gender, menopause, impaired renal function, and genetic factors (see section 1.2.2 for 
discussion of Apolipoprotein-E allele), several lifestyle factors have been associated 
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with high levels of Hcy including smoking, coffee and alcohol intake (Elias et al., 2008; 
Refsum et al., 2004). 
1.2.1.1 Homocysteine and Cardiovascular Disease 
Although some elevation of Hcy is typical in older age, high levels of Hcy through 
imbalances in production or elimination can cause oxidative stress, amyloid beta 
concentrations, plaque deposition, DNA strand breakage, and in turn apoptosis (Fuso et 
al., 2008).  Additionally, high levels of Hcy can result in damage to endothelial cells and 
inflammation of blood vessels which can lead to atherogenesis and in turn 
cerebrovascular ischemia (Ganguly & Alam, 2015).   
Despite the wellspring of recent research interest in Hcy, early evidence from 
case reports stretches back several decades.  Observations from early archival case 
studies in the 1930’s revealed an association between a genetically inherited inability to 
metabolize methionine, homocystinuria (high levels of urine homocysteine), and 
vascular insults among very young children and infants (Shih & Efron, 1970).  Additional 
case studies in the 1950’s and 1960’s showed that in the most severe cases of 
homocystinuria, children experienced pronounced cognitive deficits, thromboembolic 
disease, and early death (Carmel & Jacobson, 2002).  McCulley observed that despite 
having different enzymatic etiologies, many of these cases of homocystinuria also had 
advanced and widespread plaque buildup in major arteries resulting in arteriosclerosis 
(McCully, 2007).  These observational studies were further supported by the 
experimental work of Mann et al. (1953), which showed that atherosclerosis and 
vascular lesions could be induced in Cebus monkeys with controlled variations of 
dietary sulfur amino acids.   
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Since these early clinical studies, large epidemiological studies have provided 
additional support for the link between cardiovascular disease and high levels of 
homocysteine.  In a meta-analysis of 27 cross-sectional, case-control, and prospective 
studies, Boushey (1995) found that with every 5 μmol/L increase of total plasma 
homocysteine (tHcy) there was a 50% increase in cerebrovascular disease and 
estimated that 10% of coronary artery disease risk can be attributed to high tHcy.  
Additionally, Vollset et al. (2001) observed a dose-response relationship between higher 
levels of tHcy and all-cause mortality risk among adults 40-67 years of age (average 
follow-up 4.1 years), particularly among individuals with high risk for cardiovascular 
disease (CVD).   
These findings have been further supported by experimental epidemiology 
analysis.  A United States and Canadian population study observing the effect of folic 
acid fortification of enriched grain products from 1998-2002 showed increases in 
average blood folate concentrations, reductions in plasma total homocysteine (tHcy), 
and significant incremental decreases in stroke mortality compared with the pre-
enrichment period (1990-1997), even with adjustment for societal level changes in 
known cardiovascular risk factors such as cigarette smoking, hypertension, diabetes, 
and high total serum cholesterol (concentration ≥240 mg/dl).  Interestingly, this 
prevalence rate decline was not found in England and Wales where folate fortification 
was not required (Yang et al., 2006).   
1.2.1.2 Homocysteine and Depressive Symptoms 
 Among other well-recognized cardiovascular risk factors, high levels of Hcy have 
also been a target of interest in the development of affective disorders, particularly in 
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later life.  Much of the research on Hcy and depressive symptoms has been cross-
sectional.  Almeida et al. (2008) conducted a meta-analysis of 9 observational studies 
mainly consisting of older community-dwelling adults (N = 7,114) as well as data from 
the Health in Men Study (N  = 4,245).  Of the 9 total studies included for analysis, 6 
showed positive associations between tHcy and clinically significant levels of depressive 
symptoms (i.e., > survey cut score thresholds) or diagnosed major/minor depression 
(Almeida et al., 2005, 2008; Bjelland et al., 2003; Bottiglieri et al., 2000; Cassidy et al., 
2004; Tolmunen et al., 2004).  In all, Almeida et al. estimated that those with high levels 
of tHcy were 70% (95% CI: 1.38-2.08) more likely to have clinically significant levels of 
depressive symptoms compared those with lower levels of tHcy after adjusting for a 
range of medical comorbidities and cardiovascular risk factors.  However, two cross-
sectional studies in this analysis failed to find an association between high levels of tHcy 
and clinically significant levels of depressive symptoms.  Penninx et al. (2000) failed to 
find any association in a sample of disabled women (>=65y) and Tiemeier et al. (2002) 
did find an initial association between depression status and high tHcy, but this 
association was non-significant when adjusting for cardiovascular disease.  Although 
these cross-sectional results are promising, longitudinal research is necessary to 
determine whether Hcy contributes as a potential risk factor for depressive symptoms 
over time rather than just being associated with depressive symptomatology. 
Few prospective studies have been conducted, but results have been generally 
supportive of higher baseline tHcy predicting clinically significant levels of depressive 
symptoms at 4-year follow-up in women (Forti et al., 2010) and in men (combined 
baseline/followup risk; Tolmunen et al., 2004).  In one Korean sample, which excluded 
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baseline depression and adjusted for age, gender, education, Mini Mental State Exam 
(MMSE; Folstein, Folstein, & McHugh PR, 1975), disability, smoking, problem drinking, 
physical activity, and vascular risk, decreases in B12/B9 and increases in tHcy over a 
follow-up period of 2.4 years all predicted increased depression incidence (Kim et al., 
2008).  
1.2.2 Apolipoprotein-E4 Genotype 
Genetic factors relating to vascular function may moderate the relationship 
between tHcy and vascular depression.  The apolipoprotein (APOE) gene provides 
information necessary for the synthesis of the APOE-E protein.  This protein binds to 
lipids creating lipoproteins, which are responsible for packaging and carrying cholesterol 
and other fats through the blood stream.  Carriers of at least one APOE-E4 allele have 
been shown to have significantly higher rates of CVD and cognitive 
impairment/dementia (Eichner, 2002; Small, Rosnick, Fratiglioni, & Backman, 2004) and 
previous cross-sectional studies from the Maine-Syracuse Longitudinal Study (MSLS) 
have shown that carrying at least one APOE-E4 allele may multiply the risk associated 
with higher tHcy for lower cognitive performance (Elias et al., 2008).   
Although cross-sectional evidence for the association between depression and 
the APOE-E4 allele has been mixed, most of the studies conducted thus far have 
included small sample sizes, which may lack sufficient statistical power for detecting 
group differences in complex regression models (Evans & Rajan, 2015).  Additionally, a 
recent 5 and 9-year prospective study of older adults has shown positive associations 
between the APOE-E4 allele, depressive symptoms, and late life minor depression 
incidence (Skoog et al., 2015).  Another 1-year prospective study found no difference 
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between depressed and non-depressed older adults with regard to cognitive decline, 
but significant differences in decline when comparing depressed and non-depressed 
individuals carrying the APOE-E4 allele (Niti, Yap, Kua, & Ng, 2009).  It is unclear if the 
APOE-E4 allele affects the directional association between executive function and 
depressive symptoms, but it is possible that failing to account for APOE genotype may 
explain previously negative findings in studies using relatively invariant outcome 
measures (i.e., depression diagnosis, MMSE). 
1.3 Cognitive Performance 
 Like depression, cognitive performance can be considered a unitary construct or 
one made of up several associated factors.  Cognitive performance in this context can 
also be measured as a categorical-clinical construct or as a continuum of ability ranging 
from low to high.  Dementia is the most severe level of cognitive deficit with mild 
cognitive impairment (MCI) being considered an intermediate stage of decline from 
normal functioning (Petersen et al., 2001).  Broadly defined, MCI is cognitive decline 
which is greater than would be expected for an individual’s age or education level (often 
at least 1.5 standard deviations), but does not interfere with one’s ability to live 
independently as is seen in the case of dementia (Abner et al., 2012).  The decision to 
diagnose dementia (National Institute of Health, 2013) or MCI is often based on 
professional agreement derived from patient/ caregiver interview and cognitive testing.  
Importantly, these are clinical definitions of severity rather than etiology of cognitive 
decline, which is quite heterogeneous.  The most common conditions associated with 
dementia are Alzheimer’s disease (AD) followed by, Vascular Dementia (VaD), 
Frontotemporal Dementia (FTD), Synucleinopathies, and Huntington’s Disease 
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(National Institute of Health, 2013).  Although cognitive performance is often considered 
a continuous construct, MCI and dementia as clinical constructs can provide caregivers 
and researchers with a common language to understand the scope of the problem of 
cognitive decline among older adults. 
1.3.1 Prevalence and Course of Cognitive Impairment 
 There are upwards of 24.3 million adults living with dementia world-wide and the 
number of individuals with dementia is expected to rise to 81.1 million by 2040 (Ferri et 
al., 2005).  The average age of the U.S. population continues to rise as individuals are 
able to live longer and as such so does the burden of cognitive impairment (Ortman, 
Velkoff, & Hogan, 2014).  Currently 3-21% of individuals over the age of 65 in the U.S. 
are estimated to have MCI and roughly half of these individuals go on to develop 
dementia within five years of initial diagnosis (Gauthier et al., 2006; Manly et al., 2008; 
Petersen et al., 2001). 
 Aging and the transition from normal functioning to MCI may impact several 
cognitive domains, but some aspects of cognitive functioning are more likely to be 
impacted by the aging process.  Evidence is broadly consistent with Cattell and Horn’s 
(1967) crystalized-fluid model of aging.  Older adults tend to experience the greatest 
declines in domains associated with novel problem solving (i.e., executive function, 
working memory, processing speed, and perceptual reasoning) compared with 
performance associated with total fund of knowledge and overlearned skills (Glisky, 
2007; Harada et al., 2013).  While significant declines in any cognitive domain may be 
problematic, recent research has highlighted the particularly important role of executive 
function in maintaining functional independence. 
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1.3.2 Cognitive Impairment and Executive Function 
 Although researchers vigorously debate how to operationalize the construct of 
executive function, a general consensus on its definition has existed since its first 
introduction in Baddeley and Hitch’s model of working memory (1974).  Broadly 
speaking, executive function is a set of high-order mental processes that involve 
response inhibition, working memory, and mental flexibility (Alvarez & Emory, 2006; 
Diamond, 2014).  These core executive functions form the basis for planning and 
decision-making, troubleshooting and adapting to novel situations, and effortful 
inhibition of habitual behaviors (Jurado & Rosselli, 2007).  Significant deficits in 
executive function have been observed among older adults with MCI across clinical 
subtypes (amnesic vs. non-amnesic and single vs. multiple domain; (Brandt et al., 2009; 
Traykov et al., 2007; Zheng et al., 2012).  Additionally, these declines may precede 
disturbances in global functioning and memory and measures associated with executive 
function have been shown to have incremental utility in predicting transition from normal 
functioning to MCI/dementia (Carlson, Xue, Zhou, & Fried, 2009; Elias et al., 2000; J. K. 
Johnson, Lui, & Yaffe, 2007; Ratcliff, Dodge, Birzescu, & Ganguli, 2003). 
1.3.3 Cognitive Performance and Vascular Disease 
 The associations between cardiovascular disease and cognitive performance in 
middle and later adulthood has been well established through a series of carefully 
conducted observational studies following participants over the entire adult lifespan 
(Elias, Goodell, & Dore, 2012; Framingham Heart Study, 2016).  Much like depression, 
individuals who have experienced acute vascular attacks such as stroke are at an 
increased risk for cognitive impairment following the event.  There is a considerable 
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number of variables which affect the likelihood for cognitive impairment post-stroke, but 
prevalence estimates range from 20 – 80% depending on age, race, and diagnostic 
criteria being applied (Sun, Tan, & Yu, 2014).  These strong associations led to the 
recognition of vascular cognitive impairment/dementia, which has been expanded to 
include impairment in the presence of more silent cerebral small vessel conditions such 
as WMH and lacunar infarcts (Brickman et al., 2009; Vermeer et al., 2009).  Other 
studies have found consistent positive associations between total cardiovascular risk 
factor load and poorer cognitive performance for visual-spatial memory, working 
memory, processing speed, executive function, and global performance more generally 
(Crichton, Elias, Davey, & Alkerwi, 2014; Reis et al., 2013; Sabia et al., 2009).  
1.3.4 Cognitive Performance and Homocysteine  
As a well-recognized cardiovascular risk factor, interest in the association 
between Hcy, vascular disease, and cognitive performance has increased exponentially 
since the mid-1960’s (Robinson, 2000).  In cross-sectional analyses, tHcy level has 
been observed to be inversely associated across multiple domains of cognitive 
performance (Elias et al., 2005, 2006), and perhaps most strongly with processing 
speed and executive function  (Polito et al., 2016; West et al., 2011).  Additionally, in 3 
and 8-year prospective analysis, high baseline tHcy was found to be predictive of 
conversion from normal cognitive functioning to MCI and dementia (Gabryelewicz et al., 
2007; Seshadri et al., 2009).  Importantly, many of these findings were adjusted for a 
range of demographic factors, comorbid cardiovascular disease, and psychiatric illness.  
Individuals with vascular cognitive impairment also tend to have higher tHcy and lower 
B12 and folate compared with either stroke patients without cognitive impairment or 
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healthy controls, indicating an incremental cognitive risk with increasing levels of tHcy 
(Jiang et al., 2014).  For an extended literature review on homocysteine, vitamins, and 
cognitive functioning see Crichton, Robbins, and Elias (2015). 
Not all individuals experience similar lowering in cognitive functioning as a result 
of high tHcy.  There appears to be cross-sectional evidence for an interaction between 
age and high tHcy.  Specifically, the relationship between high tHcy and poor cognitive 
function appears to be strongest among older adults (Agrawal et al., 2015; Elias et al., 
2005).  Although many cardiovascular disease risk factors were statistically controlled in 
these studies, Agrawal et al. (2015) speculate that high levels of Hcy are more likely to 
co-occur in the presence of other aging related markers of vascular disease, which may 
have a synergistic impact on cognitive decline.     
1.4 Executive Function, Aging, and Symptoms of Depression 
 One possible mediator for the relationship between vascular risk factors such as 
tHcy and depressive symptoms may be through deficits in cognitive performance and 
more specifically deficits in executive function through vascular insult.  In the next 
sections, we discuss profiles of depression-executive dysfunction among older adults, 
followed by a review of the literature on the directional associations of cognitive 
performance and depressive symptoms and possible mechanisms of decline. 
1.4.1 Depression-Executive Dysfunction Syndrome 
There is consistent evidence that individuals experiencing the acute phase of 
depression have lowered cognitive performance across multiple domains and ages (i.e., 
executive function, attention, memory, processing speed; Hammar & Ardal, 2009).  
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Bipolar patients with high levels of tHcy tend to perform worse on the Verbal 
Comprehension and Perceptual Organization subtests of the Wechsler Adult 
Intelligence Scale – Revised (WAIS-R; Wechsler, 1981) and on the Stroop task, 
particularly among men (Permoda-Osip, Kisielewski, Dorszewska, & Rybakowski, 
2014).  However, although depressed younger adults experience a range of deficits 
compared with non-depressed peers, older depressed adults with poor vascular risk 
profiles and both young and older adults who have experienced an ischemic stroke 
experience significantly greater deficits in executive function, processing speed and gait 
slowing/impairment compared with their non-depressed peers (Hajjar et al., 2009; 
Lockwood, Alexopoulos, & van Gorp, 2002; Sanders, Bremmer, Comijs, Deeg, & 
Beekman, 2016; Sobreiro et al., 2014), indicating possible interactions between aging, 
vascular disease, and depression.  
1.4.2 Directional Associations of Executive Function and Depressive Symptoms 
It is important to determine the directionality between depressive symptoms and 
cognitive impairment because this may provide caretakers and clinicians with 
information for predicting disease trajectory.  There is a small, but burgeoning literature 
on the predictive value of low executive function and disruptions in frontostriatal 
pathways and poor antidepressant treatment response among older adults, (Sheline et 
al., 2010; Sneed et al., 2007; Tam & Lam, 2013).  Additionally, if executive functioning is 
predictive of future depressive symptoms, tests of executive functioning may be 
considered for predicting risk of future episodes following treatment (Alexopoulos, 
Kiosses, Klimstra, Kalayam, & Bruce, 2002).  Even small reductions in the development 
or severity of cognitive impairment or depressive symptoms through early detection, 
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treatment, and monitoring could have considerable positive impacts at the population 
level (Fiske et al., 2009; Zhu et al., 2013).   
So far, only a few studies have systematically reviewed the reciprocal 
relationship between depressive symptoms and cognitive functioning.  One study 
among older Hispanic adults (N = 194, Mean age = 78.5) examined this relationship 
over a 3-year period using a structural equation modeling technique known as cross-
lagged panel analysis.  In this study, the researchers measured global performance with 
3 subtests (California Verbal Learning Test, Color Trails Test, Part 2, Fuld Object 
Memory Evaluation) to represent short-term verbal learning, tracking, and short-term 
object memory.  They found that cognitive performance predicted subsequent 
depressive symptoms (CES-D), but that depressive symptoms did not predict 
subsequent cognitive performance when controlling for age, gender, and financial strain 
(Perrino, Mason, Brown, Spokane, & Szapocznik, 2008).  Given that this analysis was 
restricted to advanced-aged adults; it remains unclear if these findings can be 
generalized beyond later-life cognitive decline.  In addition, this study did not specifically 
analyze executive function outcomes (aside from inclusion in the composite) or 
adjustment for vascular risk factors which may underlie the association between 
cognitive performance and depressive symptoms in later life. 
 In another 2-year cross-lagged panel design of older adult (=> 65) primary care 
patients (N = 284), Cui, Lyness, Tu, King, and Caine (2007) found the opposite results.  
Depression diagnosis predicted subsequent executive function performance (Trails B 
and Trails B-A), but executive function did not predict depression diagnosis.  Sensitivity 
analysis revealed similar results when including both subjects with dementia and those 
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with a history of non-late onset depression.  Additionally, they rescored the Hamilton 
Depression Rating Scale (Hedlund & Viewig, 1979) to exclude vegetative symptoms 
assumed to be epiphenomena of vascular depression (i.e., decreased activities/ libido, 
gastrointestinal symptoms, weight loss, insomnia, psychomotor retardation, agitation, 
diurnal variation, and other somatic symptoms) and found similar results, indicating a 
more general longitudinal relationship between depression and executive function, 
particularly in set shifting and response inhibition.  Major strengths of this study were the 
inclusion of adjustments for chronic illness and vascular disease and the measurement 
of executive function outcomes.  However, Cui et al. failed to account for error 
covariance at baseline between depression and executive functioning, so it is unclear if 
depression diagnosis actually predicted lowered executive functioning, or if depression 
was just a concurrent risk in the presence of low executive function, and continued risk 
for poor executive function 2-years later.  Additionally, attrition (approx. 60%) was 
considerably high, with non-completers more likely to have low scores on the 
initiation/perseveration subscale of the Mattis Dementia Rating Scale.  This likely 
reduced the ability of Cui et al. to detect variation in depressive symptoms over time as 
a result of cognitive dysfunction.  Moreover, Cui et al. used multinomial logit regression 
for predicting depression diagnosis (i.e., major, minor, none) which may have further 
reduced their ability to detect subtle changes in depressive symptoms in comparison to 
the use of continuous depressive symptom scores. 
Lastly, a 2-year analysis of Korean community members (Yoon, 2014; Age > 65, 
N = 3,511), revealed that both cognitive performance (measured by Korean-Mini Mental 
State Exam) and depressive symptoms (CES-D Korean version) were negatively 
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associated in lagged analysis, indicating a possible reciprocal relationship.  The 
significant bidirectional results of Yoon’s analysis may be a reflection of adequate 
sample size to detect both causal pathways; however, their observed associations were 
also modest.  Additionally, Yoon did not include any adjustment for cardiovascular 
disease.   While the MMSE is an adequate screening measure for dementia, it is not 
designed to detect subtle variations in executive function, which may be early indicators 
for depression and cognitive impairment compared with recall (Juby, Tench, & Baker, 
2002). 
To our knowledge there has been no study to date that has systematically 
explored these relationships over longer periods of time and across a wide range of age 
groups.  This is a particularly salient issue given the long latency period for cognitive 
impairment and the potential benefits for early prediction of risks to independent living.  
It is possible that the longitudinal relationship between executive function and 
depressive symptoms change over the lifespan, becoming more strongly associated in 
older adulthood in the presence of greater allostatic load and vascular impairment 
(Lockwood et al., 2002).  Additionally, no study to date has explored the mediating role 
of executive function between tHcy and depressive symptoms.   
1.4.3 Possible Mechanisms of Decline 
It is possible that prolonged exposure to high tHcy results in cerebral 
hypoperfusion and WMH which impairs executive functioning.  Both loss of perceived 
(Lawrence, Roy, Harikrishnan, Yu, & Dabbous, 2013) and actual cognitive ability could 
explain the link between low executive function and future risk for depressive symptoms 
among older adults.   In general, depressed individuals tend to generate fewer and less 
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appropriate problem-solving strategies under cognitive load (Channon & Green, 1999).  
Poor executive function has also been associated with avoidant coping strategies 
among stroke survivors (Kegel, Dux, & Macko, 2014) which may increase the risk for 
future depressive episodes. 
It is also plausible that depression is an independent risk factor for high tHcy and 
subsequent executive dysfunction.  Among women 20-34 years of age (N = 5,051) 
depressive symptoms predicted both concurrent and subsequent lower folate levels 
over a two year period.  However, folate did not predict future depression (Kendrick et 
al., 2008).  Stressful life events may increase the risk for symptoms of depression such 
as lower physical activity and dietary disturbance which may increase risk for high tHcy 
(Okura et al., 2006; Rahman et al., 2013), poor vascular functioning, and subsequent 
executive dysfunction.  Additionally, several longitudinal analyses reviewed by Hammar 
and Ardal (2009) concluded that executive function and processing speed dysfunctions 
are not limited to depressive episodes.  These impairments tend to persist during 
symptom remission, reflecting a possible cognitive scarring effect of depression 
(Burcusa & Iacono, 2007; Gorwood, Richard-Devantoy, Baylé, & Cléry-Melun, 2014).  
However, none of these analyses accounted for cognitive performance prior to 
experiencing a depressive episode, so it is yet unclear whether depressive episodes 
represent a true risk for executive decline or if poorer executive functioning is simply a 
characteristic of those more likely to experience depressive episodes and is relatively 
invariant with regard to changes in clinical categorization.  Lastly, it is possible that tHcy 
represents a secondary marker for cerebral vascular disease rather than an 
independent cause (Wierzbicki, 2007) and variations in cognitive function and 
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depressive symptoms may be explained by already well-established vascular risk 
factors.  
1.5 Study Hypotheses in Relation to Objectives 
 No studies to our knowledge have: 1) analyzed the bidirectional associations of 
depressive symptoms and executive function in the context of a full range of other 
cognitive domains; or 2) investigated the extent to which age and APOE-E4 genotype 
moderate the prospective associations of homocysteine and depressive symptoms and 
the extent to which executive function mediates the prospective associations of 
homocysteine and depressive symptoms. 
Objectives of the proposed work with respective hypotheses were as follows: 
1. To examine the cross-sectional (at wave 6) associations of executive function 
and depressive symptoms. 
Hypothesis: Executive function will be associated with depressive symptoms at wave 6. 
2. To examine the cross-lagged prospective associations (wave 6 to wave 7) of 
executive function with depressive symptoms. 
Hypothesis:  The strength of associations of wave 6 executive function and wave 7 
depressive symptoms (adjusted for wave 6 depressive symptoms) will be stronger 
compared with the strength of associations of wave 6 depressive symptoms and wave 7 
executive function (adjusted for wave 6 cognitive function). 
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3. To determine whether age and APOE-E4 genotype (wave 6) moderate the 
prospective associations of homocysteine (wave 6) and depressive symptoms (wave 7, 
adjusted for wave 6 symptoms). 
Hypothesis:  APOE-E4 genotype and age will moderate the associations of wave 6 
homocysteine and wave 7 depressive symptoms.  Specifically, among those with higher 
homocysteine, older adults who are APOE-E4 carriers will experience the greatest 
increases in depressive symptoms.   
4. To determine the extent to which executive function mediates the associations of 
the age x APOE-E4 x homocysteine interaction (wave 6) and depressive symptoms 
(wave 7, adjusted for wave 6 symptoms). 
Hypothesis:  Wave 6 executive function will mediate the conditional association of the 
age x APOE-E4 x homocysteine interaction (wave 6) and depressive symptoms (wave 
7, adjusted for wave 6 symptoms), such that significant indirect conditional paths will be 
observed for this interaction on increases in depressive symptoms through executive 
function. 
5. To determine the specificity of the associations between executive function, 
depressive symptoms, and the above CVD-RF’s in the context of a full range of 
cognitive domains. 
Hypothesis: The associations of executive function, depressive symptoms, and the 
above CVD-RF’s will be similar across a broad range of cognitive domains.   
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2. METHODS 
2.1 The Maine-Syracuse Longitudinal Study Design 
Since its inception in 1974, the Maine Syracuse Longitudinal Study (MSLS) has 
studied the relationships between cardiovascular health and cognitive functioning for 
over three decades.  The original studies were primarily concerned with the effects of 
idiopathic and uncomplicated hypertension on cognitive functioning and have since 
expanded dramatically to include several other cardiovascular risk factors such as tHcy, 
arterial stiffness, diabetes, cholesterol, kidney function, physical activity and 
performance, and nutrition.  Along with these measures, several other measures of 
psychosocial functioning such as symptoms of depression, anxiety, and social activity 
were assessed, most often for consideration as covariates in cognitive models.  The 
MSLS includes seven waves of examination with six participant cohorts defined by time 
of entry into the study.  A total of 2464 community-dwelling individuals have participated 
in at least one examination of the MSLS (see Table 2.1). 
The first four waves of the MSLS were conducted at the SUNY Health Science 
Center in Syracuse, New York via collaboration between Merrill F. Elias, Principal 
Investigator and David H. P. Streeten, Investigator and Professor of Medicine.  In 1996, 
the MSLS acquired its own laboratory space in Syracuse while collaborating with 
medical staff at the SUNY Health Sciences Center.  This study structure continued 
through wave 6 and wave 7.   
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2.2 Sample and Design  
Data were selected from the sixth [2001-2006] and seventh [2006-2011] waves 
of the MSLS from non-institutionalized community-dwelling adults residing in Central 
New York.  Exclusions of MSLS participants were done on a study by study basis based 
on medical, and social psychological, demographic information obtained during their 
MSLS participation, including hospital and patient record (by permission).  Exclusions 
for the current study are described later.  The University of Maine Institutional Review 
Board approved this study (reference number: 2005-07-04) and informed consent was 
obtained from all participants. 
Table 2.1. Design of the MSLS 
  W1   W2   W3   W4   W5   W6    W7  
              
C1 E1 → E2 → E3 → E4 → E5 → E6 → E7 
C2   E1 → E2 → E3 → E4 → E5 → E6 
C3     E1 → E2 → E3 → E4 → E5 
C4       E1 → E2 → E3 → E4 
C5         E1 → E2 → E3 
C6           E1 → E2 
C7             E1 
W – Wave      C – Cohort       E – Examination 
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For this study participants were excluded for the following: probable dementia (n 
= 8), kidney dialysis (n = 5), and acute stroke (n = 28) at wave 6 or wave 7.  
Additionally, 196 individuals were not invited back for participation in wave 7 due to 
living outside of the Central New York area and the necessity that participants visit the 
MSLS laboratory for assessment of pulse wave analysis and pulse wave velocity.  Of 
the 822 individuals eligible for study, 103 did not return for wave 7 for other reasons 
(87.5% retention).  Although we did not exclude those with mild cognitive impairment or 
a history of depression treatment in order to obtain a wide range of continuously 
distributed data for cognitive performance and depressive symptoms, we excluded 
individuals with probable dementia (n = 8) as they were unable to complete much of the 
MSLS cognitive test battery.  Acute stroke (n = 28) and kidney dialysis (n = 5) are highly 
related to both cognitive dysfunction and symptoms of depression and those with a 
history of acute stroke were excluded due to their likely confounding effects (Elias et al., 
2009; Kauhanen et al., 1999; Sobreiro et al., 2014) on these outcomes. 
 Acute stroke is defined as suffering a focal neurological deficit of acute onset 
lasting greater than 24-hours as determine by medical record review.  A diagnosis of 
probable dementia was based on MSLS cognitive battery performance, medical record 
review, significant other interview, and consensus derived from expert committee review 
(neuropsychologists, social psychologists, and a geriatric physician) based on National 
Institute of Neurological Disorders and Communicative Diseases and 
Stroke/Alzheimer’s Disease and Related Disorders (NINDS-ADRDA; Mckhann et al., 
2011) criteria.  
2.3 Procedure 
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For waves 6 and 7 paper and pencil questionnaires including demographic data, 
job stress, sleep disturbance, Cornell Medical Index, general medical information, and 
health habits (smoking, alcohol consumption, dietary data, etc.) were completed at 
home within one week of arriving at the MSLS laboratory.   Participants arrived at the 
laboratory around 9:00 AM following a fasting period maintained since 12:00 AM unless 
they were diagnosed with diabetes mellitus and physician approval was not obtained.  
Once in the laboratory, participants provided additional medical interview information on 
physical and mental health.  Blood samples were then taken first when the participant 
arrived followed by fifteen blood pressure measurements (5 each: sitting, standing, and 
recumbent; GE DINAMAP 100DPC-120XEN; GE Healthcare), and pulse wave analysis 
(wave 7).   
Wave 6 and wave 7 assay collection methods for independent variables including 
tHcy have been described in greater detail in (Elias et al., 2006).  Plasma samples for 
tHcy and B6 were stored at -40°C and shipped to Oxford and Cambridge, UK for 
assessment.  Samples for assays of cholesterol, creatinine, plasma B9/B12, and 
glucose were stored on ice and sent to Centrex Clinical Laboratories, Syracuse, New 
York.  tHcy sample concentrations were analyzed using a fluorescence polarization 
immunoassay (Axis-Shield, Dundee, UK) on an Abbott IMx auto-analyzer (Abbott 
Laboratories, Chicago, IL, USA; Shipchandler & Moore, 1995).   The average intra-
assay variation was within accepted norms reported by the Centers for Disease Control  
(< 3.5%, CDC, 2015).  Additional details regarding assay collection have been 
described in Elias et al. (2006). 
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In addition to the assays above,  APOE genotype (collected at wave 6 or wave 7) 
was defined as those with at least one APOE-E4 allele vs. other (4/4 genotype: 2.8%; 
2/4, 3/4, and 4/4 combined genotypes: 22.8%).  APOE genotyping was derived from 
polymerase chain reaction and restriction enzyme digest with Hhal (Hixon & Vernier, 
1990) at the Neuroscience Division, Medical School, University of Birmingham, UK.  
Following assay collection, participants were provided with a light breakfast and then 
given a physical examination and were interviewed regarding medical history, 
medications, and current treatment.  Figure 2.1 displays the different locations involved 
in MSLS data collection as well as where specific assays were done. 
Figure 2.1 MSLS Structure and Assessment Locations 
 
 
 
 
 
 
 
Following interview, participants completed the MSLS Neuropsychological 
Battery of over twenty order-standardized tests from the Wechsler Memory Scale-
Revised (WMS-R), the Wechsler Adult Intelligence Scale (WAIS and WAIS-III), MMSE, 
and Boston Naming Test among several other assessments.  All cognitive measures 
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were completed in a uniform order to preserve the standardized subtest presentation 
within each scale and participants were allowed breaks as needed between subtests.  
Following the examination, participants were sent a summary of their medical and 
cognitive examination with a request that they contact their personal care provider to 
review the information.  
 Age and education were operationalized in number of years attained, sex (M/F) 
and marital status (married or living with partner/ divorced, separated, single, or 
widowed) were dichotomized as was ethnicity (Black/ Other) due to the low number of 
non-Black minority participants (Black: 6.1%, Native American: 1.0%, Hispanic: 0.4%, 
Asian: 0.1%) and to ensure consistency of coding with prior MSLS studies.  Body Mass 
Index (BMI) and obesity status (yes/no) were derived from objective measurement of 
height and weight without heavy clothing.  Self-reported number of close friendships, 
social activity (Robbins et al., 1994), and recent life events (yes/no), and co-residency 
(yes/no) were also evaluated for use as covariates. 
 The Zung Depression Inventory (ZDI; Zung, 1965) was used to measure 
symptoms of depression at every wave of the MSLS.  The ZDI is composed of 20 self-
reported, Likert scale items ranging in frequency from 1 “a little of the time” to 4 “most of 
the time” and summed to create a total raw score (see appendix A for item list).  Raw 
scores were then divided by 0.8, resulting in an index score range from 25 to 100 
(Hunter & Murphy, 2011).  At both wave 6 and wave 7, ZDI items showed good internal 
consistency (α = .80).  Index scores were used to represent the continuum of 
depressive symptom severity rather than major depressive disorder incidence.  For a 
more thorough review on dimensional scale measurement and the associations 
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between the ZDI and other depression scales see Crawford, Cayley, Lovibond, Wilson, 
& Hartley (2011). 
In order to aggregate the effect of an array of cardiovascular risk factors, the 
Framingham CVD Risk Score, which has been shown to predict 10-year risk of 
cardiovascular disease, was employed (D’Agostino et al., 2008).  The Framingham CVD 
Risk Score includes age and gender stratified weights based on assay results of total 
cholesterol (TC), high density lipoprotein (HDL), smoking status (self-report), and 
systolic blood pressure (measurement explained above) stratified by treatment status in 
addition to diabetes mellitus diagnosis status (see item weights in Appendix B).  
Estimated glomular filtration rate was determined from serum creatinine (two-point rate 
test type utilizing Johnson and Johnson VITROS instrument; Ortho Clinical Diagnostics) 
stratified by age, sex, and ethnicity (Levey, Bosch, & Lewis, 1999).  Diabetes mellitus 
was defined as those with a fasting glucose level of ≥ 126mg/dl (assay methods 
described in Elias et al., 2006) or treatment for diabetes mellitus. 
2.4 Cognitive Tests and Domains 
Cognitive performance was originally assessed using the Wechsler Adult 
Intelligence Scale (WAIS) and the Halstead-Reitan Neuropsychological Test Battery.  In 
1993, the Framingham Test Battery was included and specific tests were selected from 
these and other measures were selected to be included in the Maine Syracuse 
Longitudinal Study Test Battery at wave 6 in 2000.  Subtests and scales included in the 
battery were measured on continuous scales and used to create measures of several 
cognitive domains/composites shown in Table 2.2. 
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Principal components and factor analyses by Elias et al. (2006)., yielded four 
broad cognitive domains within a Global composite (i.e., Visual-Spatial Memory and 
Organization (VSOM), Verbal Episodic Memory, Scanning and Tracking, and Working 
Memory) derived from the Z-transformed average of 17 different subtests.  Additionally, 
the WAIS Similarities subtest has been employed as a separate measure in the MSLS 
because it loaded significantly across the above cognitive domains.  In some later 
studies an Executive Function composite was created (discussed below).  For 
descriptive purposes for this study and prior MSLS analyses, subtests were Z-
transformed, summed with their respective composite subtests, and z-transformed 
again to create standardized composite scores.  Each composite score had a mean of 
0.00 with a standard deviation of 1.00.  Similarly, the Global composite was created by 
taking the z-transformed average of all the individual subtests used in each composite, 
consistent with established MSLS practice.  For all models below, we analyzed 
cognitive performance data for the Global composite, Visual-Spatial Memory and 
Organization (VSOM), Verbal Episodic Memory, Scanning and Tracking, Working 
Memory, as well as an expanded version of the Executive Function composite 
employed in prior MSLS studies. 
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Table 2.2 Descriptions of the Cognitive Tests Contributing to Each Composite Score  
Composites/ Subtests Cognitive Ability Measured 
Verbal Episodic Memory                                                 
 Logical Memory-Immediate Recall a Immediate memory, verbal 
 Logical Memory-Delayed Recall a Delayed memory, verbal 
 Hopkins Verbal Learning Test Verbal learning and memory 
Visual-Spatial Organization/Memory                              
 Visual Reproductions-Immediate Recall a Immediate recall, visual memory, and visual-spatial problem solving 
 Visual Reproductions-Delayed Recall a Delayed recall, visual memory and visual-spatial problem solving 
 Matrix Reasoning b Abstract reasoning and pattern recognition 
 Block Design c Visual-spatial perception, organization and construction 
 Object Assembly c Speed of visual-spatial organization 
 Hooper Visual Organization Visual-spatial organization; some demands on executive function 
Scanning and Tracking  
 Trail Making A d Visual scanning and tracking; concentration and attention 
 Trail Making B d Trails A plus demands on executive function abilities 
 Digit Symbol Substitution c Psychomotor performance 
 Symbol Search b Visual processing speed 
Working Memory  
 Digit Span Forward c Attention and concentration 
 Digit Span Backward c Attention, concentration, and working memory 
 Letter-Number Sequence b Information processing while holding information in memory 
 Controlled Oral Word Associations Verbal fluency and executive functioning 
Similarities a Abstract reasoning 
Executive Function  
 Trail Making B d Trails A plus demands on executive function abilities 
 Controlled Oral Word Associations Verbal fluency and executive functioning 
Expanded Executive Function (current study)  
              Trail Making B – A Executive function/set shifting with Trails A scanning/tracking removed 
       Controlled Oral Word Associations Verbal fluency and executive functioning 
       Block Design c Visual-spatial perception, organization and construction 
       Matrix Reasoning b Abstract reasoning and pattern recognition 
 
aOrigin Wechsler Memory Scale-Revised 
bOrigin Wechsler Adult Intelligence Scale III 
cOrigin Wechsler Adult Intelligence Scale 
dOrigin Halstead-Reitan Neuropsychological Test Battery
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2.4.1 Expanded Executive Function Measure 
For this particular study, an expanded version of the original MSLS Executive 
Function composite (i.e., Controlled Oral Word Associations and Trail Making Test B-A) 
was developed.  Two additional subtests (i.e,, Block Design and Matrix Reasoning) 
were included in order to broaden the range of executive abilities assessed and to 
increase reliability of the Executive Function construct.  Subtests were included for 
study based on their theoretical relevance to different aspects of Executive Function 
(EF) and on their incremental improvement to scale reliability (wave 6 α  = .77; wave 7 α 
= .78).  The Clock Drawing Test was considered for inclusion because of its widespread 
use as a measure of Executive Function and planning (Juby, Tench, & Baker, 2002), 
but it was ultimately dropped due to a lack of performance variability (i.e., ceiling effect) 
for our sample. 
The importance of the Executive Function measure for this study warrants a 
detailed description of each of the component tests, Block Design, Matrix Reasoning, 
Controlled Oral Word Association, and Trail-Making. 
For the Block Design subtest (BD; Wechsler, 2003), participants were given 
blocks which had red, white, and half red/half white sides.  Participants were then asked 
to use the blocks to match a visual pattern presented by the examiner as quickly as 
possible.  Time-to-completion and accuracy both factor into the scoring of BD 
performance.  Participants were presented with novel patterns which became 
increasingly difficult until the participant consistently did not complete the pattern within 
the allotted time, failed to correctly reproduce the pattern, or the participant completed 
all patterns available, at which point the subtest was concluded.  BD has been shown in 
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other studies to be sensitive to variations in central executive function (updating), 
prefrontal lobe damage, and age-related decline (Brown, Brockmole, Gow, & Deary, 
2012; Friedman et al., 2006; Lezak, 2012). 
 For Matrix Reasoning (MR; Wechsler, 2003), participants were presented with an 
incomplete pattern matrix and a set of five individual patterns from which to select to 
complete the matrix pattern.  Individual patterns are selected based on concepts such 
as numbers and types of shapes, orientation, and color.  Like BD, novel pattern 
matrices were presented in standard order of increasing difficultly and participants 
continued until all levels had been completed or when they consistently failed to choose 
the correct pattern.  Participant scores were determined by number of correctly 
completed matrices.  MR was selected as an alternative index of fluid reasoning 
because unlike BD, participants were given as much time as needed to make their 
selection, reducing the overall reliance on speeded processing.   
 For Controlled Oral Word Associations (COWA; Benton, 1967; Patterson, 2011), 
participants were given one minute to verbally list as many words beginning with the 
same letter (i.e., F) as possible.  Two additional rounds were completed with different 
letters (i.e., A, S).  Participants were also asked not to repeat words, list proper nouns, 
numbers, or repeat words with different suffixes (e.g., fence and fences).  Participant 
scores were determined by number of correctly listed words.  COWA has been shown 
to correlate moderately with other measures of executive function, including the 
Wisconsin Card Sorting Task and Trail-Making Test – B  and to be sensitive to 
performance variability following antidepressant treatment for stroke patients and those 
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with frontal lobe lesions (Duff, Schoenberg, Scott, & Adams, 2005; Levin, Eisenberg, & 
Benton, 1991; Narushima, Paradiso, Moser, Jorge, & Robinson, 2007). 
For The Trail-Making Test (Jurado & Rosselli, 2007; Reitan, 1958), participants 
were given a sheet of paper which had circles distributed throughout.  In Part A, 
participants were asked to draw a trail to connect the circles in ascending order as 
quickly as possible (circles were numbered 1-25).  In Part B participants were given 
another sheet of paper, only the circles included both numbers (1-13) and letters (A-L).  
Participants were then asked to draw a trail to connect the circles in ascending order 
alternating between numbers and letters (i.e., 1-A-2-B-3-C) as quickly as possible.  
Time taken to complete the tasks was recorded in seconds, with less time representing 
greater performance.  The log-transformed difference in seconds between Part B and 
Part A (TMT B-A) was calculated to minimize the effect of processing speed and to 
better isolate demand on set shifting and response inhibition represented by Part B (Cui 
et al., 2007; Jurado & Rosselli, 2007).   
2.5 Statistical Methods 
 Statistical analyses initially consisted of selecting theoretically relevant 
covariates, analyzing bivariate associations between covariates, the Executive Function 
composite and symptoms of depression.  Lastly, analysis of path models was 
conducted with basic and extended sets of covariates.   
2.5.1 Covariate Selection 
 Previous studies have identified several theoretically relevant covariates with 
respect to Executive Function, tHcy, and symptoms of depression (see Appendix C).  
   36 
After identifying commonly occurring covariates in the literature, covariates were 
eliminated initially based on a lack of association with any of the following: Executive 
Function, tHcy, or symptoms of depression (p > .10).  
A basic covariate set was employed in all analyses (age, sex, education, 
ethnicity, and marital status) and other covariates were included based on their 
contributions to model fit as represented by reductions in the χ2 statistic.  However, 
since the χ2 statistic is almost always significant (p < .05) with large sample sizes (n > 
400; Kenny, 2015), other measures were employed which are not as prone to type-one 
error (χ2/df, root mean squared error of approximation (RMSEA), and comparative fit 
index (CFI).  Although many of these variables did not have a considerable negative 
impact on model fit statistics, diminishing returns on model fit were observed.  Once 
model fit indices were observed to be satisfactory, several covariates were excluded in 
order to achieve model parsimony.   
2.5.2 Cross-Lagged Panel Design 
 We utilized a structural equation modeling technique known as cross-lagged 
panel design (CLPD, SPSS V.24 AMOS).  In this study, wave 6 Executive Function 
(EF1) and depressive symptoms (D1) and wave 7 Executive Function (EF2) and 
depressive symptoms (D2) are the variables of interest.  A simplified version of the 
CLPD employed in this study is displayed in Figure 2.2 below. This CLPD produces 6 
possible associations, 2 synchronous (cross-sectional; D1-EF1, D2- EF2), 2 auto-
correlational (D1-D2, EF1-EF2) and 2 cross-lagged (EF1-D2, D1-EF2).  This design 
allows the 2 cross-lagged prospective associations between Executive Function and 
depressive symptoms to be adjusted by wave 6 levels in order to examine change over 
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time.  Significant synchronous associations between EF1-D1 or EF2-D2 in the absence 
of other associations would indicate that the relationships between Executive Function 
and depressive symptoms may be epiphenomenal, but not indicative of predictive 
change.  Significant associations for only one of the cross-lagged paths imply a model 
of unidirectional change over 5-years.  Significant associations between the auto-
correlations of D1-D2 and EF1-EF2, but not between the associations of the cross-lags 
(EF1-D2 and EF1-D2) would indicate that Executive Function and depressive symptoms 
are causally unassociated.  Lastly, if the cross-lag of EF1-D2 > D1-EF2 then Executive 
Function predicts depressive symptoms more than depressive symptoms predicts 
Executive Function. 
Figure 2.2 Simplified Model of Cross-Lagged Panel Design 
_____________________________________________________________________ 
 
______________________________________________________________________ 
D1 and D2 are depressive symptoms at wave 6 and wave 7 respectively.  EF1 and EF2 
are Executive Function at wave 6 and wave 7 respectively.  Straight lines represent 
regression paths and curved lines represent paths of covariation. 
 
After models were identified for Executive Function and ZDI as independent 
predictors, we assessed the specificity of these relationships by substituting each 
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cognitive domain (Global composite, Visual-Spatial Memory and Organization, Verbal 
Episodic Memory, Scanning and Tracking, Working Memory) in the place of Executive 
Function to determine the specificity of these associations.  Cognitive domains were 
measured as latent variables with subtest errors from wave 6 being covaried with 
subtest errors from wave 7.  ZDI was measured as a continuous observed variable from 
the scoring scheme above.  Pathways were assessed first in the presence of basic 
covariates (age, sex, education, ethnicity, and marital status) and then in the presence 
of an extended set of covariates. 
2.5.3 Conditional Mediation Analyses 
 After the temporal precedence of Executive Function and depressive symptoms 
was determined via CLPD analysis, the direct effects of wave 6 APOE-E4 genotype x 
age x tHcy interactions on wave 7 depressive symptoms adjusted for wave 6 depressive 
symptoms was examined.  Simultaneously, we examined the indirect associations of 
these three-way interactions and depressive symptoms through Executive Function.  All 
conditional mediation models were also adjusted for lower-order two-way interactions 
and their respective main effects in addition to model covariates from the CLPD.  Since 
tHcy was of primary interest in these models, the direct and indirect (through Executive 
Function/cognitive function) effects of tHcy on depressive symptoms were included in 
the conditional mediation tables below.  As was true for the CLPD analyses above, we 
substituted each cognitive domain individually in the place of Executive Function in 
these models to determine the specificity of these associations.   
 We estimated the parameters of our models from eligible participants with data at 
wave 6 and wave 7 using maximum likelihood estimation for all analyses (CLPD EF 
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Extended models, 21.1% any missing data; Conditional Mediation EF Extended models 
9.0% any missing data).  Standard errors and confidence intervals were estimated using 
SPSS V.24 AMOS software bootstrapping techniques (5000 samples). 
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3. RESULTS 
3.1 Attrition, Demographic, and Health Variables 
Table 3.1 shows demographic and health characteristics at wave 6 for 
participants who completed both wave 6 and wave 7 (n = 719) and those who only 
completed wave 6 because they were either unavailable (n = 103) or not invited back (n 
= 196) for wave 7 analyses due to living outside of the Central New York area.  
Compared with those that only completed wave 6 (n = 299), a lower proportion of those 
that completed both waves were Black, were previously diagnosed with depression, and 
were marginally less likely to be diabetic or taking psychotropic medications (p’s < .05).  
Additionally, those that completed both waves had higher levels of functional 
performance and marginally higher total cholesterol as well as lower levels of 
depressive symptoms (ZDI), tHcy, and HDL (p’s < .10).  Lastly, those that completed 
both waves performed better across all domains of cognitive performance (p’s < .01).  
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Table 3.1 Wave 6 Demographic and Health Characteristics                    
 Participation Period   
Variable  
Wave 6 only  
n = 299 
Both Waves  
n = 719 
P-value 
Age (years), M(SD)1  62.31(14.77) 62.09(11.93)  
Sex (% female)  55.6 59.7  
Education (years), M(SD)  14.52(2.84) 14.64(2.71)  
Ethnicity (% Black)  10.7 6.1 * 
Marital Status (% Cohabitating/Married)  59.1 64.7  
Recent Life Events (%)  23.0 22.0  
Social Activity, M(SD)1  20.81(5.94) 21.19(5.17)  
Cohabitation (% living w/ others)  76.0 77.5  
Close Relationships, M(SD)  6.48(9.43) 6.39(6.63)  
Functional Performance M(SD)1      1.17(1.26) 0.84(1.23) *** 
Zung Depression Inventory M(SD)      44.01(9.38) 41.87(9.42) ** 
Cigarettes/week, M(SD)1      11.94(43.06) 8.48(34.06)  
Alcohol drinks/week, M(SD)      1.64(3.74) 1.47(2.54)  
Body Mass Index, M(SD)  29.43(6.12) 29.18(5.84)  
Homocysteine(μmol/L), M(SD)1  10.69(4.56) 9.66(3.14) ** 
B12, nmol/L, M(SD)1  485.03(291.78) 475.20(233.94)  
B6, nmol/L M(SD)1  97.54 (105.15) 92.01(84.78)  
B9, ng/L M(SD)1  15.82(5.87) 15.24(5.30)  
C-Reactive Protein, M(SD)  4.38(4.65) 3.99(4.55)  
Mean Arterial Pressure, M(SD)  91.28(12.47) 90.50(12.74)  
Total Cholesterol (Mg/DL), M(SD)  197.26(41.94) 202.82(39.44) + 
HDL, mg/DL, M(SD)  51.85(14.79) 53.88(15.41) + 
LDL, mg/DL, M(SD)  118.34(33.94) 121.18(33.07)  
Triglycerides, mg/DL, M(SD)  146.67(123.98) 142.95(108.11)  
EPI-GFR, ml/min, M(SD)1  76.11(21.04) 77.86(16.43)  
Framingham Score, M(SD)  13.45(6.04) 13.12(5.62)  
Hypertension Meds (%)  55.0 51.0  
Psychotropic Meds (%)  25.0 15.0 *** 
Diabetes (%)  16.0 11.0 + 
Previous Depression Diagnosis (%)  20.0 12.0 * 
Cardiovascular Disease (%)  15.4 12.8  
APOE-E4 (%)  23.3 28.0  
Global Composite, M(SD)1   -0.14(1.04) 0.12(0.89) *** 
Verbal Episodic Memory, M(SD)1   -0.13(1.07) 0.10(0.90) ** 
Visual Spatial Organization and Memory, M(SD)1  -.12(1.21) 0.10(0.92) ** 
Scanning and Tracking, M(SD)1  -0.10(1.02) 0.10(0.93) ** 
Working Memory, M(SD)  -.11(1.01) 0.09(0.95) ** 
Expanded Executive Function Composite, M(SD)1  -0.14(1.03) 0.10(0.93) ** 
+ p < .10, *p < .05, ** p < .01 *** p < .001 
1Equal variances not assumed 
Categorical variables assessed with Fisher’s exact test 
Cognitive Performance measured in z-score units     
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3.2 Associations of Executive Function and other Domains 
 As expected, significant associations between the wave 6 Expanded Executive 
Function composite and all other domains of cognitive performance were observed (p’s 
< .001).  Rather than emerging as an orthogonal construct, Executive Function was 
highly associated with Global cognitive performance, Visual-Spatial Organization and 
Memory (r’s > 0.80) and was moderately associated with Verbal Episodic Memory, 
Working Memory, and Scanning and Tracking (0.20 < r’s < 0.80).  Lastly, Executive 
Function was moderately associated with the Similarities subtest which has been shown 
in prior MSLS analyses to load significantly across all cognitive domains (Elias et al., 
2006).  Table 3.2 displays zero-order correlations for all wave 6 domains of cognitive 
performance. 
Table 3.2 Zero-Order Correlations of Wave 6 Cognitive Domains   
Wave 6 
Variable 
Executive 
Function 
Global Verbal 
Episodic 
Memory 
Working 
Memory 
Scanning & 
Tracking 
VSOM 
 
Executive 
Function 
- 0.887*** 0.472*** 0.645*** 0.740*** 0.847*** 
Global  - 0.692*** 0.711*** 0.839*** 0.886*** 
Verbal 
Episodic 
Memory 
  - 0.391*** 0.437*** 0.504*** 
Working 
Memory 
   - 0.500*** 0.448*** 
Scanning 
& Tracking 
    - 0.690*** 
VSOM      - 
Similarities  0.612*** 0.663*** 0.442*** 0.387*** 0.452*** 0.612*** 
***p<.001, **p<.01, *p<.05 +p<.10 
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3.3 Covariate Selection 
 The following variables measured at wave 6 and wave 7 were considered based 
on the their common inclusion in the literature: age, sex, education, marital status, 
ethnicity, diabetes mellitus status, CVD status, Framingham CVD Risk Score, social 
activity, number of close relationships, smoking, cohabitation, measures of obesity, 
alcohol consumption, high density lipoprotein (HDL), low density lipoprotein (LDL), 
triglycerides, total cholesterol (TC), estimated glomular filtration rate/creatinine, vitamins 
B6/B9/B12, hypertension status and continuously measured systolic/diastolic blood 
pressure, physical function deficits (Dearborn, Robbins, & Elias, 2015), psychotropic 
medications/anti-depressive medications, and previous depression diagnosis requiring 
treatment (Appendix B). 
 Of the variables considered above, measures of hypertension, smoking, 
estimated glomular filtration rate/creatinine, vitamins B9/B12, HDL, TC, triglycerides, 
and smoking were dropped due to lack of associations with depressive symptoms (p’s > 
.10).   Measures of obesity, psychotropic/anti-depressive medications, and previous 
depression diagnosis requiring treatment were dropped due to lack of associations with 
Executive Function (p’s > .10).  Alcohol consumption, cohabitation status, number of 
close relationships, social activity, and LDL were dropped due to lack of associations 
with tHcy (p’s > .10).  
Table 3.3 shows model covariates surviving backward elimination.  Physical 
function deficits, diabetes mellitus status, vitamin B6, and CVD status were considered 
for analysis based on their associations with Executive Function, depressive symptoms 
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and tHcy, but were ultimately dropped because they did not contribute significantly to 
model fit.   
Table 3.3 Zero-Order Associations of Model Covariates Surviving Backward Elimination  
Wave 6 
Variable 
tHcy Age Sex Education Marital 
Status 
Ethnicity Framingham 
Executive 
Function 
-0.151*** -0.394*** -0.020 0.386*** 0.188*** -0.266*** -0.355*** 
Global -0.194*** -0.491*** 0.073+ 0.390*** 0.185*** -0.185*** -0.442*** 
Verbal 
Episodic 
Memory 
-0.116** -0.361*** 0.124** 0.237*** 0.057 -0.143*** -0.305*** 
Working 
Memory 
-0.106** -0.217*** 0.052 0.278*** 0.096* -0.214*** -0.256*** 
Scanning 
& 
Tracking 
-0.234*** -0.523*** 0.138*** 0.307*** 0.145*** -0.229*** -0.444*** 
VSOM -0.154*** -0.462*** -0.017 0.340*** 0.231*** -0.245*** -0.390*** 
ZDI 0.066+ 0.090* 0.091* -0.191*** -0.153*** 0.073+ 0.069+ 
tHcy - 0.200*** -0.261*** -0.052 0.058 0.077* 0.289*** 
***p<.001, **p<.01, *p<.05 +p<.10 
Wave 7 ZDI (tHcy r  = 0.088, p = .023; Framingham r = 0.100, p = .010) 
3.4 Cross-Sectional Associations of Cognitive Performance and Depressive 
Symptoms  
After adjustment for basic demographic covariates (Basic model: age, sex, 
education, ethnicity, and marital status) and cardiovascular risk factors (Extended 
model: tHcy and Framingham Risk Score), Executive Function was associated inversely 
with depressive symptom severity (Table 3.4).  Additionally, all other domains of 
cognitive performance were associated inversely (p’s < .05) with depressive symptom 
severity with the exception of Working Memory (p > .10).  These wave 6 model 
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covariates were employed in the prospective CLPD based on the methods described 
above.  
Table 3.4 Cross-Sectional Standardized (β) and Unstandardized (b) Regression 
Coefficients of Wave 6 Cognitive Function Predicting Symptoms of Depression 
 Basic Model Extended Model 
Cognitive Outcome β b SE β b SE 
Executive Function -0.149*** -0.012*** 0.003 -0.146*** -0.012*** 0.003 
Global -0.157*** -0.005*** 0.001 -0.156*** -0.005*** 0.001 
Verbal Episodic Memory -0.077* -0.007* 0.003 -0.078* -0.007* 0.003 
Working Memory -0.022 -0.001 0.003 -0.022 -0.001 0.003 
Scanning & Tracking -0.140*** -0.011*** 0.002 -0.137*** -0.011*** 0.002 
VSOM -0.169*** -0.013*** 0.002 -0.169*** -0.013*** 0.002 
***p <.001; * *p < 0.01; *p < 0.05 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + homocysteine, + Framingham Risk Score  
3.5 5-year Cross-Lagged Associations of Cognitive Performance and Depressive 
Symptoms 
 CLPD model fit statistics illustrated in Figure 2.2 are displayed in Table 3.5 
below.  Although model χ2 statistics were significant across all cognitive domain 
models, RMSEA statistics range from excellent (Executive Function and Scanning and 
Tracking RMSEA’s ≤ .05) to satisfactory (Global, Working Memory, Verbal Episodic 
Memory, Visual Spatial Organization and Memory (RMSEA’s ≥ .06 < .09). These fit 
statistics were similar across other measures of fit (CFI and χ2/df) with the exception of 
Global cognitive performance models (CFI- Basic model = 0.811, CFI-Extended model 
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= 0.816), which likely suffered from the comparatively larger number (n = 17) and 
variability of subtests in the Global composite.   
Table 3.5 Model Fit Statistics for 5-Year Cross-Lagged Panel Analyses 
 CFI 
(Basic/Extended) 
RMSEA 
(Basic/Extended) 
χ2(df) 
(Basic/Extended) 
p-value 
(all) 
Executive 
Function 
0.979 / 0.979 0.044 / 0.034 139.142(58) /  
161.840(70) 
<0.001 
     
Global  0.811 / 0.816 0.080 / 0.077 4539.375(814) / 
4648.440(882) 
<0.001 
     
Working 
Memory 
0.945 / 0.954 0.065 / 0.060 235.583(58) / 
248.316(70) 
<0.001 
     
Verbal 
Episodic 
Memory 
0.955 / 0.962 0.086 / 0.076 213.055(34) / 
216.637(42) 
<0.001 
     
Scanning and 
Tracking 
0.983 / 0.984 0.047 / 0.044 166.133(58) / 
166.777(70) 
<0.001 
     
VSOM 0.937 / 0.940 0.069 / 0.066 521.986(118) / 
573.539(138) 
<0.001 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + homocysteine, + Framingham Risk Score  
CFI = Confirmatory Fit Index 
RMSEA = Root Mean Squared Error of Approximation 
3.5.1 Cognitive Function and Changes in Depressive Symptoms 
After adjustment for wave 6 depressive symptom severity, demographic 
covariates (Basic) and cardiovascular risk factors (Extended), lower wave 6 Executive 
Function predicted increased depressive symptom severity at wave 7 (p < .05).  This 
pattern of results was similar across other wave 6 domains of cognitive functioning, 
including Global cognitive performance, Scanning and Tracking, and Visual-Spatial 
Reasoning and Memory (p’s < .05; VSOM Extended model p < .10).  However, unlike 
Executive Function, wave 6 Verbal Episodic Memory and Working Memory failed to 
predict changes in depressive symptoms at wave 7.  These results are displayed in 
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Table 3.6 below.  Additionally, a simplified version of the Executive Function CLPD 
Extended Model is displayed in Figure 3.1 below.  CLPD figures for the other remaining 
cognitive domains are displayed in Appendix D. 
Table 3.6 Cross-Lagged Standardized (β) and Unstandardized (b) Regression 
Coefficients of Wave 6 Cognitive Function and Wave 7 Symptoms of Depression 
 Basic Model Extended Model 
Cognitive Outcome      β      b   SE    β     b SE 
Executive Function -0.108* -1.348* 0.613 -0.099* -1.241* 0.614 
Global -0.136** -4.587** 1.658 -0.130** -4.383** 1.653 
Verbal Episodic Memory -0.044 -0.474 0.365 -0.046 -0.493 0.364 
Working Memory -0.027 -0.427 0.605 -0.024 -0.319 0.605 
Scanning & Tracking -0.170*** -2.188*** 0.599 -0.167*** -2.145*** 0.598 
VSOM -0.093* -1.189* 0.572 -0.086+ -1.107+ 0.572 
***p < .001; * *p < 0.01; *p < 0.05, p < .10 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + homocysteine, + Framingham Risk Score  
 
 
  
   48 
Figure 3.1 Cross-Lagged Panel Analysis Executive Function Extended Model 
 
 
Fit Indices 
RMSE = 0.034  
χ2(70) = 161.840, p < .001 
χ2/df = 2.312  
CFI = 0.979 
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3.5.2 Depressive Symptoms and Changes in Cognitive Function  
These CLPD analyses were conducted simultaneously with those presented 
Table 3.6 with adjustment for wave 6 Executive Function to determine the 5-year 
predictive value of wave 6 depressive symptoms on changes in Executive Function at 
wave 7.  These analyses were repeated in separate models with adjustment for all other 
wave 6 domains of cognitive function.  After adjustment for demographic covariates 
(Basic) and cardiovascular risk factors (Extended), wave 6 depressive symptoms failed 
to predict changes in Executive Function at wave 7 (p < .05).  Similarly, wave 6 
depressive symptoms failed to predict changes in wave 7 Global cognitive performance 
and Visual-Spatial Organization and Memory, and Verbal Episodic Memory (p’s > .05).  
However, unlike Executive Function, higher wave 6 depressive symptoms were 
associated with decreased performance in wave 7 Working Memory and Scanning and 
Tracking (p’s < .05).  These results are presented in Table 3.7 below.   
Table 3.7 Cross-lagged Standardized (β) and Unstandardized (b) Regression 
Coefficients of Wave 6 Symptoms of Depression and Wave 7 Cognitive Function 
 Basic Model Extended Model 
Cognitive Outcome β b SE β         b SE 
Executive Function -0.031 -.003 .002 -0.034 -0.003 0.002 
Global -0.020 -0.001 0.001 -0.022 -0.001 0.001 
Verbal Episodic Memory -0.049+ -0.005+ 0.003 -0.047+ -0.005+ 0.003 
Working Memory -0.084** -0.005** 0.002 -0.086** -0.006** 0.002 
Scanning & Tracking -0.040* -0.003* 0.002 -0.042* -0.004* 0.002 
VSOM -0.003 0.000 0.002 -0.005 0.000 0.002 
* *p < 0.01; *p < 0.05; + p < .10 
Basic model = wave 6 age, sex, education, ethnicity, marital status 
Extended model = Basic model + homocysteine, + Framingham Risk Score  
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3.5.3 Directional Findings of Cross-Lagged Panel Analyses 
The results suggest significant unidirectional relationships with lower wave 6 
Executive Function predicting increases in depressive symptoms at wave 7, but wave 6 
depressive symptoms not predicting changes in wave 7 Executive Function.  Similar 
unidirectional results were found for Global cognitive performance, and Visual-Spatial 
Organization and Memory.  Different unidirectional patterns were found for Working 
Memory, with higher wave 6 depressive symptoms predicting increases in wave 7 
Working Memory.  Lastly an inverse bidirectional trend was observed between 
Scanning and Tracking and depressive symptoms, though wave 6 Scanning and 
Tracking was a stronger predictor (Extended model: βstd = -0.167) of changes in wave 
7 depressive symptoms compared with wave 6 depressive symptoms as a predictor of 
changes in wave 7 Scanning and Tracking (Extended model: βstd = -0.042).  
3.6 Conditional (Moderated by Age x APOE-E4) Effects of Homocysteine Mediated 
Through Cognitive Function on Wave 7 Depressive Symptoms 
 Figure 3.2 and Figure 3.3 show simplified models of individual component path 
coefficients for predicting wave 7 depressive symptoms from which direct, indirect, and 
total effects can be calculated for the Basic and Extended model, respectively.  Basic 
wave 6 model covariates and wave 6 depressive symptoms were repeated from CLPD 
analyses and Extended models included adjustments for wave 6 Framingham Risk 
Score.  Table 3.8 and Table 3.9 show the direct and indirect effects of tHcy, 
Framingham Risk Score, and age x tHcy x APOE-E4 genotype interactions (adjusted for 
all corresponding two-way interactions) in relation to wave 6 Executive Function, other 
domains of cognitive performance, and wave 7 depressive symptoms for the Basic and 
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Extended model, respectively.  In all mediation analyses, age and tHcy were Z-
transformed for clarity of interpretation.   
 Model χ2 statistics remained significant across all cognitive domain models and 
RMSEA statistics again ranged from excellent (Executive Function and Scanning and 
Tracking RMSEA’s ≤ .05) to adequate (Working Memory, Verbal Episodic Memory, and 
Visual-Spatial Organization and Memory RMSEA’s ≤ .073) with the exception again of 
Global performance models (Extended model RMSEA = .097).  
3.6.1 Age x tHcy x APOE-E4 Effects 
For both the Basic and Extended models, the direct paths of wave 6 tHcy x age  
x APOE-E4 interaction were significantly associated with changes in wave 7 depressive 
symptoms across all cognitive models (p’s < .01, Executive Function p < .05).  However, 
wave 6 tHcy x age x APOE-E4 interactions were unrelated to wave 6 performance 
across all cognitive domains. Lastly the indirect paths from wave 6 age x tHcy x APOE-
E4 interaction to changes in wave 7 depressive symptoms as mediated by cognitive 
performance were not significantly different from zero in all models (p’s > .05) with the 
exception of Scanning and Tracking (p < .05).   
3.6.2 tHcy Effects 
 The main effect of wave 6 tHcy was not associated with changes in wave 7 
depressive symptoms or wave 6 cognitive performance across all models (p’s > .10).  
Additionally, no mediation of the indirect path from wave 6 tHcy to wave 7 changes in 
depressive symptoms was observed for any cognitive domains (p’s > .10). 
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3.6.3 Framingham Risk Score Effects  
Wave 6 Framingham Risk Score was positively associated with changes in wave 
7 depressive symptoms in all cognitive models (p’s < .05; Global p < .10) with the 
exception of Executive Function (p > .10).  Additionally, wave 6 Framingham Risk Score 
was inversely associated with wave 6 Executive Function (p < .01), Working Memory,  
Visual Spatial Organization and Memory (p’s < .05), and marginally inversely associated 
with wave 6 Global cognitive performance (p < .10).  Additionally, no mediation of the 
indirect path from wave 6 Framingham Risk Score to wave 7 changes in depressive 
symptoms was observed for any cognitive domains (p’s > .10), with the exception of 
Global cognitive performance (p < .05). 
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Figure 3.2 Simplified Path Basic Model Showing Conditional Indirect Effects of tHcy 
(Moderated by Age and APOE-E4) on Symptoms of Depression 
______________________________________________________________________ 
 
______________________________________________________________________
Lower-order two-way interactions (age x tHcy, age x APOE-E4 & tHcy x APOE-E4) 
adjusted with wave 6 covariates 
                                
 
 
 
 
 
 
 
 
 
 
A3 
   54 
Figure 3.3 Simplified Path Extended Model Showing Conditional Indirect Effects of tHcy 
(Moderated by Age and APOE-E4) on Symptoms of Depression  
______________________________________________________________________ 
 
______________________________________________________________________
Lower-order two-way interactions (age x tHcy, age x APOE-E4 & tHcy x APOE-E4) 
adjusted with wave 6 covariates 
A3 
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Table 3.8 Component Path Coefficients (b) For the Direct and Indirect Effects of Age, tHcy, and APOE-E4 on Symptoms 
of Depression Mediated through Cognitive Function (Basic Model). 
       Direct Effect Component Path Indirect Effect Component 
Path 
     Indirect 
Effect 
 
Cognitive Outcome   c’1 c’3     a1     a3 b1 ab1 ab3  
           
Executive Function  b 0.056 -2.433**  0.007 0.053 -0.939 -0.006 -0.049 
  se 0.520 0.811  0.050 0.094 0.735 0.062 0.121 
Global  b 0.060 -2.313**  0.004 0.039 -3.755* -0.041 -0.146 
  se 0.519 -0.812  0.029 0.013 1.808 0.054 0.139 
Verbal Episodic 
Memory 
 b 0.070 -2.376**  0.041 0.066 -0.410 -0.017 -0.027 
  se 0.508 0.804  0.039 0.096 0.408 0.063 0.028 
Working Memory  b 0.052 -2.514**  0.043 0.062 0.033 0.002 0.001 
  se 0.511 0.805  0.035 0.082 0.636 0.036 0.069 
Scanning & 
Tracking 
 b 0.010 -2.199*  -0.024 0.167 -1.850** 0.044 -0.309* 
  se 0.515 0.809  0.033 0.079 0.622 0.067 0.184 
VSOM  b 0.063 -2.446**  0.016 0.028 -0.962 -0.015 -0.027 
  se 0.517 0.807  0.039 0.082 0.642 0.047 0.098 
* *p < 0.01; *p < 0.05; +p < .10 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function 
C’3 = Direct effect of tHcy x age x APOE-E4 interaction on wave 7 ZDI unmediated by cognitive function 
A1 = Indirect component effect of tHcy on cognitive function 
A3 = Indirect component effect of tHcy x age x APOE-E4 interaction on cognitive function 
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function 
Ab3 = Indirect effect of tHcy x age x APOE-E4 interaction on ZDI 7 mediated through cognitive function 
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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Table 3.9 Component Path Coefficients (b) For the Direct and Indirect Effects of Age, tHcy, and APOE-E4 on Symptoms 
of Depression Mediated through Cognitive Function (Extended Model). 
              Direct Effect Component Path Indirect Effect 
Component Path 
  Indirect Effect 
Cognitive Outcome   c’1 c’2 c’3  a1 a2 a3 b1 ab1 ab2 ab3 
              
Executive Function  b 0.015 0.144 -2.049**  0.007 -0.017** 0.055 -0.809 -0.012 0.014 -0.044 
  se 0.514 0.077 0.815  0.051 0.007 0.092 0.736 0.058 0.015 0.111 
Global  b -0.008 0.143+ -2.343**  0.006 -0.004+ 0.040 -3.518* -0.021 0.014* -0.139 
  se 0.513 0.076 0.817  0.013 0.002 0.029 1.793 0.053 0.010 0.133 
Verbal Episodic 
Memory 
 b -0.006 0.162* -2.104**  0.039 0.003 0.066 -0.422 -0.017 -0.001 -0.028 
  se 0.501 0.076 0.808  0.039 0.008 0.095 0.412 0.028 0.005 0.064 
Working Memory  b -0.029 0.163* -2.546**  0.050 -0.015* 0.064 0.159 0.008 -0.002 0.010 
  se 0.504 0.077 0.808  0.035 0.006 0.080 0.637 0.040 0.010 0.070 
Scanning & 
Tracking 
 b -0.061 0.151* -2.223*  -0.022 -0.004 0.167* -1.816** -0.023 0.008 -0.304* 
  se 0.509 0.077 0.813  0.033 0.006 0.079 0.617 0.066 0.012 0.182 
VSOM  b -0.007 0.146* -2.471**  0.021 -0.012* 0.029 -0.863 -0.018 0.010 -0.025 
  se 0.511 0.076 0.811  0.040 0.006 0.081 0.641 0.046 0.010 0.081 
* *p < 0.01; *p < 0.05; +p < .10 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + Framingham Risk Score 
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function 
C’2 = Direct effect of Framingham Risk Score on wave 7 ZDI unmediated by cognitive function 
C’3 = Direct effect of tHcy x age x APOE-E4 interaction on wave 7 ZDI unmediated by cognitive function 
A1 = Indirect component effect of tHcy on cognitive function 
A2 = Indirect component effect of Framingham Risk Score on cognitive function 
A3 = Indirect component effect of tHcy x age x APOE-E4 interaction on cognitive function 
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function 
Ab2 = Indirect effect of Framingham Risk Score on ZDI 7 mediated through cognitive function 
Ab3 = Indirect effect of tHcy x age x APOE-E4 interaction on ZDI 7 mediated through cognitive function 
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI 
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3.7 Conditional Effects of Wave 6 Homocysteine (Moderated by Age) on Wave 7 
Depressive Symptoms Mediated Through Cognitive Function  
 Due to significant three-way interactions between age, tHcy and APOE-E4 
genotype, mediation path analyses were conducted separately for APOE-E4 carriers (n 
= 189) and non-carriers (n = 483).  Basic and Extended model covariates were repeated 
from the above mediation analyses with adjustment for the main effects of age and tHcy 
in determining the associations of tHcy x age interactions, cognitive function, and wave 
7 depressive symptoms.  Overall model fit statistics will be addressed, followed by 
conditional mediation analyses by APOE-E4 genotype. 
3.7.1 Model Fit Statistics 
Prior model fit analyses were conducted with the combined statistical power of 
APOE-E4 carriers and non-carriers combined (n = 719), resulting in significant χ2 
statistics, indicating that the data were significantly different from what would be 
expected.  Although in APOE-E4 carrier (n = 189) Extended models χ2 statistics 
remained significant, the Executive Function Extended model was not significantly 
different from model expectations (p > 0.05).  Additionally, RMSEA statistics indicated 
excellent (Executive Function RMSEA = 0.028) to adequate fit (RMSEA’s ≤ 0.076) with 
the exception of the Global Composite models (RMSEA = 0.112).  Since there were 
considerably more APOE-E4 non-carriers in our sample (n = 483), Extended model χ2 
statistics remained significant across all domains.  However, RMSEA’s were in the 
excellent (Executive Function RMSEA = 0.049) to adequate range (RMSEA’s ≤ 0.076) 
with the exception of the Global Composite and Working Memory models (RMSEA’s ≤ 
0.108).   
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3.7.2 APOE-E4 Carriers – Age x tHcy Interaction Effects  
Among APOE-E4 carriers in the Basic model (Table 3.10), significant 
associations were observed for the direct path of wave 6 age x tHcy interactions to 
changes in wave 7 depressive symptoms for the Visual-Spatial Organization and 
Memory and Working Memory models (p’s < .05).  However, in the Extended models 
(Table 3.11), these direct associations fell to marginal significance for across all 
cognitive models (p’s < .10) with the exception of Scanning and Tracking (p > .10).  In 
the Basic and Extended models, wave 6 age x tHcy interactions were not associated 
with wave 6 performance for any cognitive domain, nor did any domain of cognitive 
performance significantly mediate the indirect association of wave 6 age x tHcy 
interactions and changes in wave 7 depressive symptoms (p’s > .10; Basic model 
Executive Function p < .10). 
3.7.3 APOE-E4 Carriers – tHcy Effects  
For both the Basic and Extended models for APOE-E4 carriers (Table 3.10 and 
Table 3.11), wave 6 tHcy was not associated with wave 6 performance for any cognitive 
domain (p’s > .10).  Additionally, wave 6 tHcy failed to predict changes in wave 7 
depressive symptoms. Lastly, the indirect path from wave 6 tHcy and changes in wave 
7 depressive symptoms was not significantly mediated by any cognitive domain (p’s 
>.10).  
3.7.4 APOE-E4 Carriers – Framingham Risk Score Effects  
 For APOE-E4 carriers, wave 6 Framingham Risk Score was inversely associated 
with Global cognitive performance and Working Memory (p’s < .05; Table 3.11) and 
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marginally inversely associated with Executive Function (p < .10).  However, wave 6 
Framingham Risk Score failed to predict changes in wave 7 depressive symptoms.  
Lastly, the path from wave 6 Framingham Risk Score to changes in wave 7 depressive 
symptoms was not significantly mediated by any domain of cognitive performance (p’s > 
.10). 
3.7.5 APOE-E4 Non-Carriers – Age x tHcy Interaction Effects 
Among APOE-E4 non-carriers in the Extended models (Table 3.13), significant 
positive associations between wave 6 tHcy x age and changes in wave 7 depressive 
symptoms were observed across all cognitive models (p’s < .05; Global p < .10).  
However, wave 6 tHcy x age interactions failed to significantly predict wave 6 cognitive 
performance in all cognitive models with the exception of Scanning in Tracking (Table 
3.12 Basic model p < .05) and Global cognitive performance (Basic model p < .10; 
Extended model p < .05).  Lastly, the path from wave 6 age x interactions to changes in 
wave 7 depressive symptoms was not significantly mediated by any domain of cognitive 
performance (p’s > .10) with the exceptions of Scanning and Tracking (Basic and 
Extended model p’s < .05) and Global cognitive performance (Basic and Extended 
model p’s < .10). 
3.7.6 APOE-E4 Non-Carriers – tHcy Effects 
For both the Basic and Extended models for APOE-E4 non-carriers (Table 3.12 
and Table 3.13), wave 6 tHcy was not associated with wave 6 performance for any 
cognitive domain (p’s > .10) with the exception of Scanning and Tracking (Extended 
model p < .05).  Additionally, wave 6 tHcy failed to predict changes in wave 7 
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depressive symptoms across all cognitive models (p’s > .10).  Lastly, the path from 
wave 6 tHcy and changes in wave 7 depressive symptoms was not significantly 
mediated by any cognitive domain (p’s >.10). 
3.7.7 APOE-E4 Non-Carriers – Framingham Risk Score Effects 
 For APOE-E4 non-carriers, wave 6 Framingham Risk Score was not associated 
with performance in any cognitive domain (p’s > .10) with the exception of Executive 
Function (Table 3.13; p < .10).  Additionally, wave 6 Framingham Risk Score failed to 
predict changes in wave 7 depressive symptoms (p’s > .10).  Lastly, the path from wave 
6 Framingham Risk Score to changes in wave 7 depressive symptoms was not 
significantly mediated by any domain of cognitive performance (p’s > .10). 
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Table 3.10 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of 
Depression Mediated through Cognitive Function (Basic Model) for APOE-E4 Carriers 
       Direct Effect Component Path Indirect Effect Component 
Path 
     Indirect 
Effect 
 
Cognitive Outcome   c’1 c’3     a1     a3 b1 ab1 ab3  
           
Executive Function  b 0.450 -1.110  -0.068 0.025 -1.883 0.128 -0.046+ 
  se 0.662 0.643  0.075 0.084 1.377 0.208 0.203 
Global  b 0.550 -1.106+  0.010 0.012 -3.860 0.040 -0.046 
  se 0.648 0.622  0.027 0.028 3.501 0.138 0.141 
Verbal Episodic 
Memory 
 b 0.566 -1.126+  -0.022 0.068 -0.466 0.010 -0.032 
  se 0.654 0.616  0.087 0.082 0.763 0.075 0.094 
Working Memory  b 0.592 -1.171*  -0.083 0.050 0.250 -0.021 0.013 
  se 0.651 0.623  0.076 0.070 1.139 0.133 0.100 
Scanning & 
Tracking 
 b 0.661 -0.964+  0.029 0.072 -2.664* -0.078 -0.193 
  se 0.637 0.616  0.065 0.067 1.264 0.196 0.215 
VSOM  b 0.560 -1.160*  -0.027 -0.007 -1.100 0.029 0.007 
  se 0.652 0.623  0.067 0.075 1.244 0.121 0.123 
* *p < 0.01; *p < 0.05, +p < .10 
N = 189 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function 
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function 
A1 = Indirect component effect of tHcy on cognitive function 
A3 = Indirect component effect of tHcy x age interaction on cognitive function 
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function 
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function 
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI 
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Table 3.11 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of 
Depression Mediated through Cognitive Function (Extended Model) for APOE-E4 Carriers 
              Direct Effect Component Path Indirect Effect Component Path  Indirect Effect 
Cognitive Outcome   c’1 c’2 c’3  a1 a2 a3 b1 ab1 ab2 ab3 
              
Executive Function  b 0.351 0.135 -1.067+  -0.048 -0.024+ 0.016 -1.715 0.083 0.041 -0.027 
  se 0.656 0.147 0.651  0.072 0.014 0.082 1.414 0.185 0.044 0.189 
Global  b 0.626 0.145 -1.061+  -0.004 -0.008* 0.009 -3.401 0.013 0.028 -0.031 
  se 0.644 0.143 0.629  0.026 0.005 0.027 3.486 0.122 0.030 0.129 
Verbal Episodic 
Memory 
 b 0.420 0.178 -1.061+  -0.028 0.007 0.071 -0.485 0.014 -0.003 -0.034 
  se 0.623 0.140 0.623  0.085 0.018 0.087 0.766 0.078 0.018 0.095 
Working Memory  b 0.455 0.192 -1.117+  -0.057 -0.030* 0.039 0.522 -0.030 -0.016 0.020 
  se 0.646 0.144 0.628  0.071 0.012 0.067 1.174 0.112 0.039 0.096 
Scanning & 
Tracking 
 b 0.535 0.151 -0.916  0.037 -0.009 0.069 -2.570* -0.096 0.024 -0.178 
  se 0.637 0.143 0.624  0.065 0.010 0.067 1.275 0.191 0.031 0.210 
VSOM  b 0.434 0.156 -1.104+  -0.012 -0.017 -0.013 -0.958 0.012 0.017 0.012 
  se 0.646 0.143 0.631  0.065 0.013 0.074 1.258 0.110 0.029 0.117 
* *p < 0.01; *p < 0.05, +p < .10 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + Framingham Risk Score 
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function 
C’2 = Direct effect of Framingham Risk Score on wave 7 ZDI unmediated by cognitive function 
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function 
A1 = Indirect component effect of tHcy on cognitive function 
A2 = Indirect component effect of Framingham Risk Score on cognitive function 
A3 = Indirect component effect of tHcy x age interaction on cognitive function 
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function 
Ab2 = Indirect effect of Framingham Risk Score on ZDI 7 mediated through cognitive function 
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function 
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI
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Table 3.12 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of 
Depression Mediated through Cognitive Function (Basic Model) for APOE-E4 Non-Carriers 
       Direct Effect Component Path Indirect Effect Component 
Path 
     Indirect 
Effect 
 
Cognitive Outcome   c’1 c’3     a1     a3 b1 ab1 ab3  
           
Executive Function  b 0.094 1.034*  0.009 -0.027 -0.645 -0.006 0.018 
  se 0.528 0.518  0.049 0.050 0.892 0.057 0.065 
Global  b 0.092 0.946+  0.003 -0.022+ -3.995+ -0.011 0.087+ 
  se 0.530 0.517  0.012 0.015 2.483 0.054 0.083 
Verbal Episodic 
Memory 
 b 0.108 1.055*  0.049 -0.029 -0.342 -0.017 0.010 
  se -0.519 0.517  0.038 0.049 0.485 0.033 0.034 
Working Memory  b 0.098 1.064*  0.041 -0.006 -0.154 -0.006 0.001 
  se 0.524 0.518  0.033 0.043 0.814 0.042 0.036 
Scanning & 
Tracking 
 b 0.039 0.955+  -0.033 -0.074* -1.587* 0.053 0.118* 
  se 0.523 0.511  0.033 0.033 0.777 0.066 0.082 
VSOM  b 0.099 1.004+  0.015 -0.031 -1.027 -0.016 0.032 
  se 0.530 0.517  0.036 0.047 0.791 0.050 0.070 
* *p < 0.01; *p < 0.05, p < .10 
N = 483 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function 
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function 
A1 = Indirect component effect of tHcy on cognitive function 
A3 = Indirect component effect of tHcy x age interaction on cognitive function 
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function 
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function 
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI 
 
 
   
 64 
Table 3.13 Component Path Coefficients (b) for the Direct and Indirect Effects of Age and tHcy on Symptoms of 
Depression Mediated through Cognitive Function (Extended Model) for APOE-E4 Non-Carriers 
              Direct Effect Component Path Indirect Effect Component Path  Indirect Effect 
Cognitive Outcome   c’1 c’2 c’3  a1 a2 a3 b1 ab1 ab2 ab3 
              
Executive Function  b 0.027 0.132 1.100*  0.016 -0.014+ -0.034 -0.539 -0.009 0.008 0.018 
  se 0.526 0.091 0.517  0.050 0.008 0.050 0.889 0.056 0.016 0.064 
Global  b 0.026 0.130 1.011+  0.004 -0.002 -0.023* -3.827+ -0.015 0.009 0.088+ 
  se 0.527 0.091 0.517  0.012 0.002 0.015 2.460 0.054 0.011 0.082 
Verbal Episodic 
Memory 
 b 0.037 0.140 1.119*  0.048 0.000 0.029 -0.340 -0.016 0.000 0.010 
  se 0.517 0.091 0.517  0.039 0.009 0.049 0.489 0.033 0.006 0.034 
Working Memory  b 0.025 0.140 1.131*  0.046 -0.010 -0.011 -0.068 -0.003 0.001 0.001 
  se 0.521 0.092 0.518  0.034 0.007 0.044 0.816 0.046 0.010 0.037 
Scanning & 
Tracking 
 b -0.029 0.136 1.019*  -0.032* -0.002 -0.075 -1.569* 0.051 -0.002 -0.073* 
  se 0.522 0.091 0.512  0.034 0.007 0.034 0.772 0.066 0.013 0.083 
VSOM  b 0.033 0.130 1.070*  0.020 -0.010 -0.036 -0.944 -0.019 0.009 0.034 
  se 0.527 0.090 0.517  0.037 0.007 0.047 0.787 0.050 0.011 0.050 
* *p < 0.01; *p < 0.05, + p < .10 
N = 483 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + Framingham Risk Score 
C’1 = Direct effect of tHcy on wave 7 ZDI unmediated by cognitive function 
C’2 = Direct effect of Framingham Risk Score on wave 7 ZDI unmediated by cognitive function 
C’3 = Direct effect of tHcy x age interaction on wave 7 ZDI unmediated by cognitive function 
A1 = Indirect component effect of tHcy on cognitive function 
A2 = Indirect component effect of Framingham Risk Score on cognitive function 
A3 = Indirect component effect of tHcy x age interaction on cognitive function 
Ab1 = Indirect effect of tHcy on ZDI 7 mediated through cognitive function 
Ab2 = Indirect effect of Framingham Risk Score on ZDI 7 mediated through cognitive function 
Ab3 = Indirect effect of tHcy x age interaction on ZDI 7 mediated through cognitive function 
B1 = Indirect component effect of wave 6 cognitive function on wave 7 ZDI 
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3.8 Johnson-Neyman Moderation Analysis   
 In order to explore the continuous nature of age’s moderation effect on the 
association between wave 6 tHcy and changes in wave 7 depressive symptoms, we 
employed the Johnson-Neyman technique (P. O. Johnson & Fay, 1950).  Unlike 
traditional “pick a point” moderation analysis, which requires the investigator to analyze 
age categories according to arbitrary cut-off points to observe differential effects of the 
predictor variable (tHcy), the Johnson-Neyman technique uses the entirety of available 
data to estimate the age regions where the effects of wave 6 tHcy on changes in wave 7 
depressive symptoms are statistically significant.  In addition to specificity, this 
technique has the benefit of preserving statistical power compared with splitting the data 
according to arbitrary cut-off points.  Due to the significant associations of the three-way 
interactions of wave 6 age x tHcy x APOE-E4 and changes in wave 7 depressive 
symptoms, the interaction of age x tHcy was analyzed separately for APOE-E4 carriers 
and non-carriers.  Although age x tHcy interactions did not reach the level of 
significance in the APOE-E4-carrier Extended models, the marginal trend for age x tHcy 
interactions (p < 0.10) warranted further exploration as did the apparent inversion of the 
wave 6 age x tHcy interaction effect on changes in wave 7 depressive symptoms for 
APOE-E4 non-carriers. 
 Johnson-Neyman moderation analyses are shown in Table 3.14 for APOE-E4 
non-carriers by 10th, 25th, 50th, 75, and 90th age percentile ranks.  In the Basic model, 
the effect of wave 6 tHcy on changes in wave 7 depressive symptoms was significant (p 
< .05) for individuals ≥ 75.39 years of age.  These results were similar for the Extended 
model with significant effects for individuals ≥ 74.33 years of age (p < .05), indicating 
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increases in symptoms of depression with higher levels of tHcy among older adults.  
Figure 3.4 shows the simple slope of wave 6 tHcy on changes in wave 7 depressive 
symptoms by age for APOE non-carriers for the extended model. 
Table 3.14 Effects (b) of Wave 6 tHcy by Age Category on Wave 7 Symptoms of 
Depression for APOE-E4 Non-Carriers 
 Basic Model Extended Model 
Age       b SE  b SE 
47  -1.245 0.865  -1.431 0.869 
54  -0.636 0.616  -0.767 0.619 
62  0.060 0.427  -0.008 0.429 
71  0.843+ 0.497  0.845+ 0.498 
78  1.452* 0.712  1.414* 0.678 
* *p < 0.01; *p < 0.05, + p < .10 
N = 483 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + Framingham Risk Score 
Johnson-Neyman moderation analyses are shown in Table 3.15 for APOE-E4 
carriers by 10th, 25th, 50th, 75, and 90th age percentile ranks as well.  Age category cut 
offs differed slightly, but sensitivity analysis did not indicate any significant differences of 
mean age between the groups (MD = 1.650. SE = 1.018, p = .11) nor considerable 
differences in age variance (p > 0.25).  As expected, no significant associations were 
observed for APOE-E4 carriers.  However, there was a marginal association (p < .10) of 
higher wave 6 tHcy and increases in wave 7 depressive symptoms for adults ≤ 51 years 
of age in the Basic model and ≤ 45 years of age in the Extended model. Figure 3.5 
shows the simple slope of wave 6 tHcy on changes in wave 7 depressive symptoms by 
age for APOE carriers for the extended model. 
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Table 3.15 Effects (b) of Wave 6 tHcy by Age Category on Wave 7 Symptoms of 
Depression for APOE-E4 Carriers 
 Basic Model Extended Model 
Age       b SE  b SE 
45  2.192+ 1.124  1.912+ 1.140 
51  1.645+ 0.864  1.396 0.882 
61  0.733 0.676  0.536 0.690 
69  0.004 0.859  -0.153 0.865 
77  -0.726 1.215  -0.841 1.215 
* *p < 0.01; *p < 0.05, + p < .10 
N = 189 
Basic model = wave 6 age, sex, education, ethnicity, marital status, and ZDI 
Extended model = Basic model + Framingham Risk Score 
3.9 Sensitivity Analysis: Conditional Effects of Wave 6 Framingham Risk Score 
(Moderated by Age and APOE-E4) on Wave 7 Depressive Symptoms 
  Due to significant conditional effects of wave 6 tHcy on changes in wave 7 
depressive symptoms (moderated by age and APOE-E4), we explored whether these 
same three-way interaction patterns held for Framingham Risk score (age x APOE-E4 x 
Framingham Risk Score).  In a Basic model, we adjusted for wave 6 age, sex, 
education, ethnicity, and marital status as well as lower-order two-way interactions and 
main effects of APOE-E4 and Framingham Risk Score.  In the Basic model, we did not 
observe a significant three-way interaction effect of age x APOE x Framingham Risk 
Score on changes in wave 7 depressive symptoms (b = -0.778, SE = 0.540, p = 0.16).  
These results remained similar with the addition of tHcy as a model covariate (b = -
0.769, SE = 0.540, p = 0.16).   
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Figure 3.4 tHcy Effect Slope (b) and 95% Confidence Intervals by Age for APOE-E4 
Non-Carriers  
_____________________________________________________________________ 
  
 
______________________________________________________________________ 
Figure obtained using Johnson-Neyman technique. 
 
Solid vertical line represents area of significance (p < 0.05).  Significant positive effects of wave 6 tHcy on 
wave 7 ZDI were found for individuals ≥ 74.33 years of age. 
 
Adjusted for wave 6 age, sex, education, marital status, ZDI and Framingham Score 
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Figure 3.5 tHcy Effect Slope (b) and 95% Confidence Intervals by Age for APOE-E4 
Carriers   
______________________________________________________________________ 
 
 
____________________________________________________________________________________ 
Figure obtained using Johnson-Neyman technique. 
 
No significant moderation of slope.   
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3.10 Summary of Results 
 In wave 6 cross-sectional analyses, higher Executive Function and other 
cognitive functions, with the exception of Working Memory, were associated with lower 
levels of depressive symptoms adjusted for age, sex, education, ethnicity, tHcy, and 
Framingham Risk Score.  In CLPD analyses bidirectional associations between 
symptoms of depression and Executive Function were not observed.  Rather, 
unidirectional associations were observed with higher wave 6 Executive Function 
predicting decreases in symptoms of depression at wave 7.  These associations were 
also observed for wave 6 Global cognitive function and Visual-Spatial Organization and 
Memory function in relation to wave 7 depressive symptoms.  Higher wave 6 depressive 
symptoms were not undirectionally associated with lowered wave 7 Executive Function 
and a similar pattern of non-significant results was observed for all other domains of 
cognitive function with the exception of Working Memory.  Finally, unlike Executive 
Function, Scanning and Tracking was bidirectionally associated with depressive 
symptoms, however the inverse association of wave 6 Scanning and Tracking and wave 
7 depressive symptoms was stronger than what was observed of wave 6 depressive 
symptoms and wave 7 Scanning and Tracking. 
 For conditional mediation models the direct path of age x tHcy x APOE 
interactions were significantly associated with changes in depressive symptoms at wave 
7, however, there was no direct main effect of tHcy or indirect effect through Executive 
Function or other domains of cognitive functioning.  However, higher Framingham Risk 
scores at wave 6 were directly associated with increases in wave 7 depressive 
symptoms and were indirectly associated with depressive symptoms through Executive 
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Function.  Similar to Executive Function, significant indirect paths through Working 
Memory and Visual-Spatial Organization and Memory were also observed. 
 Among APOE-E4 carriers, Framingham Risk score was not indirectly associated 
with changes in depressive symptoms through Executive Function. However, this path 
was significantly different from zero through Working Memory and Global Function.  
Additionally APOE-E4 carriers with higher tHcy experienced marginal increases in 
depressive symptoms at less than 51 years of age.  For APOE-E4 non-carriers, higher 
tHcy was also associated with increases in depressive symptoms, but these 
associations were delayed until after 74 years of age. 
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4. DISCUSSION 
The purpose of this study was to explore the associations of Executive Function, 
homocysteine, and depressive symptoms.  In the first phase of the study, we explored 
the cross-sectional associations of cognitive function and symptoms of depression.  In 
the following phase, we explored the bidirectional associations of Executive Function 
and other domains of cognitive function and depressive symptoms.  Based on the 
results of this phase, we explored the conditional mediation effect of homocysteine and 
the Framingham Risk Score (modified by age and APOE-E4 status) through Executive 
Function on changes in depressive symptoms.  At each phase, we explored the 
specificity of these relationships with Executive Function as compared with a full range 
of cognitive domains. 
4.1 Cross-Sectional Association of Symptoms of Depression and Cognitive 
Performance 
 Our cross-sectional results are consistent with those observed by Hammar & 
Ardal (2009).  Several domains of cognitive performance were negatively associated 
with symptoms of depression both with and without adjustment for age, sex, education, 
ethnicity, and CVD-RF’s (Framingham Risk Score and tHcy).  This is also consistent 
with cross-sectional studies which have found that individuals with vascular disease and 
high CVD risk profiles tend to be at a higher risk for depressive symptoms and lower 
cognitive performance  (Crichton et al., 2014; Hajjar et al., 2009; Kauhanen et al., 
1999).  However, few studies have examined the longitudinal associations of these 
variables, which has limited our ability to infer directionality, and no studies to our 
knowledge have examined the potential mediating role of cognitive function on changes 
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in symptoms as moderated by age and APOe-E4 genotype.  Because the vascular 
depression hypothesis asserts that aging–related processes may underlie the 
associations of cognitive function and symptoms of depression, it is epidemiologically 
relevant to analyze these relationships over time in the context of an ever-aging U.S. 
population (Ortman et al., 2014).  Moreover, the longitudinal design of this study allowed 
us to adjust for baseline cognitive performance and depressive symptoms, which adds 
to the predictive value of aging models.  In the following sections, we discuss the 
longitudinal findings of this study as they relate to the broader base of literature, 
strengths and limitations, future directions, and their clinical implications. 
4.2 Directional Associations of Symptoms of Depression and Cognitive 
Performance 
 Inverse unidirectional associations were observed, with several domains of 
cognitive performance predicting changes in symptoms of depression over the 5-year 
interim, however, the reverse association was largely not found.  These results are 
consistent with the observations of Perrino et al. (2008) who assessed general cognitive 
function using the Color Trails Test, Part 2 (D’Elia, Satz, Uchiyama, & White, 1996), the 
California Verbal Learning Test (Delis, Kramer, Kaplan, & Ober, 2000), and the Fuld 
Object Memory Evaluation (Fuld, 1977).  However, these results differ from those 
obtained by Cui, Lyness, Tu, King, and Caine (2007), who found that depression 
diagnosis unidrectionally predicted Trails-B and Trails B-A times, but not the reverse.   
There are a few possible reasons why our results differ from those obtained by 
Cui, Lyness, Tu, King, and Caine (2007).  Firstly, unlike the current study and Perrino et 
al. (2008), Cui et al. did not adjust for baseline cognitive functioning, which may have 
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otherwise diminished the predictive power of depression diagnosis.  Second, Cui et al. 
defined depression diagnosis using multinomial coding (3 levels) rather than measuring 
symptoms continuously as was the case in the current study and in Perrino et al.  This 
may have in turn reduced the predictive power of cognitive function in their study.  
Lastly, although both the current study and Cui et al. adjusted for CVD-RF’s and used 
Executive Function measures as predictors, the current study and Perrino et al. 
measured Executive Function (and cognitive function more broadly) using multiple 
subtests to estimate performance, likely increasing the reliability of the measure.  This is 
a particularly important point as individual measures of Executive Function have been 
shown to have poorer reliability compared with other measures of cognitive function 
(i.e., processing speed; Miyake et al., 2000), possibly because performance on tasks 
used to index Executive Function may depend on developing an optimal strategy which 
might occur in a stepwise rather than a continuous fashion, leading to an immediate 
increase in performance.  Conversely, should one repeat the same strategy, 
performance may increase only slightly, stay the same or may become inappropriate, 
leading to an immediate drop in performance (Rabbit, Lowe, & Shilling, 2001).  Using 
multiple measures to estimate Executive Function may better capture the diverse nature 
of the construct without considering all measurement variance as random error.  
4.3 Homocysteine and Depressive Symptoms 
 Zero-order correlations showed inconsistent inverse associations between wave 
6 tHcy and wave 6 and wave 7 depressive symptoms and the main effects of tHcy on 
depressive symptoms were largely absent in the presence of demographic and CVD-RF 
covariates for a pooled-age sample of community-dwelling adults.  These results are 
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contrary to those observed in a meta-analysis by Almeida et al. (2008).  However, 
almost all of the studies included in the meta-analysis observed differences in tHcy level 
by MDD/clinically significant symptom status rather than depressive symptoms 
measured continuously.   While measuring these variables continuously increases 
statistical power, it is possible that the associations between tHcy and symptoms of 
depression are more subtle with a healthy community-dwelling, sample due to a 
restriction of symptom severity.  
4.4 Homocysteine Moderated by Age and APOE-E4 
 Although the main effects of tHcy on changes in depressive symptoms were 
largely absent after adjusting for a range of demographic and CVD-RF’s in an age-
pooled sample (adjusted for three and two-way interactions), as hypothesized, the 
effects of tHcy on 5-year changes in symptoms were dependent upon age and APOE-
E4 status.  It is possible that the reason Almeida et al. (2008) observed mainly positive 
associations between high tHcy and depression was that their analyses were almost 
entirely limited to older adults.  Contrary to our expectations however, positive 
associations between the age x tHcy interaction and changes in depressive symptoms 
were observed for APOE-E4 non-carriers rather than APOE-E4 carriers.  It is important 
to note that research thus far on APOE-E4 status and depressive symptoms is limited 
and has been inconsistent (Niti et al., 2009; Skoog et al., 2015).  This is the first study to 
our knowledge to explore the moderating effect of APOE-E4 in concert with tHcy for 
changes in depressive symptoms.   
Although these findings seem contradictory, it is also important to note that 
associations between the interaction of age x tHcy by APOE-E4 genotype and wave 7 
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ZDI reflect residual change scores from wave 6 to wave 7 (adjusted for wave 6 ZDI) 
rather than absolute levels of depressive symptoms.  This is evidenced by high levels of 
tHcy never emerging as a protective factor for depressive symptoms for APOE-E4 
carriers, as associations of high tHcy and advancing age never approached significance 
for symptom reduction.  However, we did observe marginally higher risk for symptom 
increases among younger to middle-aged adult APOE-E4 carriers.  Second, we 
observed among APOE-E4 non-carriers that the risks associated with high tHcy for 
increases in depressive symptoms were not significant until after 74 years of age.  
Rather than APOE-E4 non-carrier status presenting as a symptom risk factor as a 
function of high tHcy compared with carrier status, the direction and strength of these 
associations may represent a compression or delay of the negative symptom effects of 
high tHcy for APOE-E4 non-carriers compared with carriers. 
4.5 Framingham Risk Score in Relation to Depressive Symptoms and Cognitive 
Performance 
 Although associations for Framingham Risk Score were not hypothesized a 
priori, it is worth noting that higher Framingham Risk Score was associated with 
increases in depressive symptoms and lower levels of cognitive performance for the 
combined sample (n = 719) across several cognitive models.  Additionally, Framingham 
Risk Score was a more consistent predictor of cognitive performance than either the 
interaction of tHcy x age x APOE-E4 or the main effect of tHcy.  One possible reason for 
these findings is that compared with tHcy, Framingham Risk Score represents a more 
complete CVD-RF profile.  However, there is also evidence that inclusion of tHcy level 
in Framingham Risk Scores may increase predictive value for CVD outcomes 
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(Veeranna et al., 2011).  Additionally, the predictive value of tHcy for cognitive deficit 
and CVD may depend on advanced age (Elias et al., 2005; Rodondi et al., 2012).  
Though Framingham Risk Score is a well-recognized measure for assessing CVD risk 
and has been consistently associated with higher depressive symptoms and lower 
cognitive functioning in cross-sectional studies (Hajjar et al., 2009; Kaffashian et al., 
2011; Kivimäki et al., 2012), other analyses have failed to find associations between 
Framingham/Stroke Risk Scores and subsequent increases in depressive symptoms 
(Cui et al., 2007; Kivimäki et al., 2012).  To our knowledge, this is the first study to 
observe these associations across such a wide age range of adults.  
4.6 Specificity of Executive Function Findings 
The focus of this study was to extend the vascular depression hypothesis 
literature, which primarily implicates Executive Function decline as a cognitive risk factor 
for increases in depressive symptoms and MDD relapse.  However, our results indicate 
that the associations between cognitive function, CVD-RF’s, and symptoms of 
depression are more general rather than specific to Executive Function. 
First, the CLPD findings of this study appeared to be similar across several 
domains of cognitive function, including Global cognitive performance, Visual-Spatial 
Organization and Memory, and Scanning and Tracking, indicating that the associations 
of cognitive function and depressive symptoms are more general rather than specific, 
consistent with the meta-analysis by Hammar & Ardal (2009).  It is important to note that 
this may be in large part due to the composition of our Executive Function variable, 
which includes subtests from the Visual-Spatial Organization and Memory (i.e., Matrix 
Reasoning and Block Design) and Scanning and Tracking (i.e., Trails A and Trails B) 
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domains, which are all also contained within the Global composite.   However, the 
Working Memory domain also contained a subtest within our measure of Executive 
Function (i.e., Controlled Oral Word Association) and the reverse unidirectional finding 
(ZDI → WM) was observed.  This indicates that shared subtest makeup does not alone 
explain these generalized findings.   
Our expanded measure of Executive Function was built upon established MSLS 
operationalizations of the construct which emphasized planning and set shifting (Elias et 
al., 2006; Robbins, Elias, Budge, Brennan, & Elias, 2005).  However, several subtests 
across other MSLS composites which were not included in our expanded measure also 
require fluid ability and related demands upon aspects of Executive Function such as 
attention, Working Memory, and set shifting (Table 2.2), making the true distinction of 
our Executive Function composite and other domains unclear.  Additionally, 
independent of overlaps with fluid ability composites in the MSLS, measures such as 
Matrix Reasoning and Block design have been represented both in the WAIS and the 
Cattell Culture Fair Tests (Matrix Reasoning) as surrogates of fluid ability (Cattell, 1949; 
Wechsler, 1981).   
Although Executive Function and other several other domains of cognitive 
function largely predicted unidirectional changes in depressive symptoms, in conditional 
mediation analyses, Executive Function and other cognitive functions broadly were 
inconsistent/weak mediators of the paths from wave 6 CVD-RF’s (tHcy, tHcy x age x 
APOE-E4 interaction, Framingham Risk Score) and changes in depressive symptoms.  
Although there were some exceptions to the pattern of broadly null mediation results, it 
is important to note the inherently increased risk for type 1 error in multiple model 
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mediation testing.  As such, the pattern of null mediation results reflects a generalized 
finding similar to the CLPD despite being contrary to our mediation hypotheses. 
Perhaps the most obvious reason for the generalized pattern of our cognitive 
models is that Executive Function is a heterogeneous construct composed of several 
moderately associated components (e.g., Working Memory, response inhibition, mental 
flexibility; Alvarez & Emory, 2006; Diamond, 2014) which fall within the conceptual 
umbrella of fluid ability.  Previous MSLS principal component analyses have established 
that a single factor within the MSLS battery accounts for about 62% of performance 
variance with the next most explanatory factor accounting for just 14% of measurement 
variance (Elias et al., 2006).  Furthermore, the expanded Executive Function composite 
utilized in this study was moderately to highly with all other domains of cognitive 
function including the Similarities subtest which loads significantly across all domains 
(Table 3.2; Elias et al., 2006).  Although many validated models of cognitive ability 
incorporate the construct of a general cognitive ability whereby many faculties are 
positively associated (i.e., G-factor), meta-analyses of hundreds of factor analytic 
studies support the conceptual distinction between fluid (i.e., novel problem solving) and 
crystalized (i.e., long-term memory/overlearned) abilities (Carroll, 1993; McArdle & 
Hofer, 2014) despite considerable overlap.  However, the distinction between general 
fluid ability and Executive Function is less clear and there is no established standard for 
what constitutes an Executive Function task versus a task of general fluid ability.  
Others have observed that a single factor structure represents a better model fit than a 
two-factor structure when applying statistical models to fluid ability subtests within the 
Woodcock-Johnson Tests of Cognitive Abilities (i.e., Analysis Synthesis, Concept 
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Formation, and Verbal Analogies) and individual tasks designed to measure aspects of 
Executive Function (i.e., Category Test, Trail Making Test-B, Wisconsin Card Sorting 
Test; Decker, Hill, & Dean, 2007).  Although there is evidence for the incremental 
predictive power of Executive Function in maintaining activities of daily living over global 
cognitive ability, it is quite possible that disruption of any associated Executive/fluid 
ability is likely to also be associated with general cognitive decline  (J. K. Johnson et al., 
2007; Zheng et al., 2012).  This may indicate that although Executive Function 
impairment is a central symptom of the depression executive dysfunction 
syndrome/vascular depression hypothesis, general cognitive impairment/decline 
represents a common symptom among those with high levels of depressive symptoms 
and lowered Executive Function (Alexopoulos et al., 2002).   
Lastly, it is possible that lack of specificity of the associations of Executive 
Function and symptoms of depression compared with other domains of cognitive 
performance are due in part to the content of our chosen measure of depressive 
symptoms.  The Zung Depression Inventory has been shown to be a reliable and valid 
measure of general depressive symptoms (Thurber, Snow, & Honts, 2002).  However, 
there is some evidence that individuals with Executive Function deficits, and poor 
vascular profiles are more likely to exhibit a particular profile of depressive symptoms 
which includes higher psychomotor retardation, and less severe expressions of guilt, 
symptom insight, and agitation compared to depressed individuals without a poor 
vascular profile/Executive Function profile (Alexopoulos et al., 2002; Hajjar et al., 2009; 
Sobreiro et al., 2014).  The focus of this study and of much of the literature (Hammar & 
Ardal, 2009) on the associations of cognitive performance with a wide aggregated array 
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of depressive symptoms, rather than a specific subset of symptoms associated more 
with vascular depression may explain why Executive Function failed to distinguish itself 
from other domains of cognitive function. 
4.7 Mechanisms of Change 
Our results relating to the Framingham Risk Score are consistent with prior 
cross-sectional and longitudinal analyses which have found that those with healthier 
cardiovascular profiles (i.e., Cardiovascular Health Score; Crichton et al., 2014; Reis et 
al., 2013) are likelier to have higher cognitive performance across a range of domains 
rather than within a specific area of functioning such as Executive Function.  
Additionally, although we did not observe consistent cognitive performance mediation 
for the associations of CVD-RF’s and changes in symptoms of depression, we did 
observe a generalized independent predictor role of cognitive performance for changes 
in symptoms.  As such, although many studies exploring the vascular depression 
hypothesis implicate the importance of Executive Function in maintaining activities of 
daily living and emotional regulation, it is quite possible that cerebrovascular 
mechanisms underlying these relationships may implicate a more generalized role of 
cognitive performance. 
First, one of the issues in exploring the specificity of the role of Executive 
Function is finding a universal definition for vascular depression.  Some researchers 
have focused on functional outcomes such as reduced Executive Function 
performance/treatment response (depression executive dysfunction syndrome) and 
others have focused on pathophysiology using neuroimaging techniques (Sneed, 
Rindskopf, Steffens, Krishnan, & Roose, 2008).  As previously mentioned, older adults 
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with poor vascular health and depression tend to exhibit irregularities and decreased 
volume of the prefrontal cortex which is implicated in Executive Function (Jurado & 
Rosselli, 2007; W. D. Taylor, Aizenstein, & Alexopoulos, 2014).  However, older adults 
with poor vascular profiles are also at higher risk for lower hippocampal/total brain 
volume and diffuse small vessel disease as evidenced by the presence of WMH in MRI 
studies (Prins et al., 2005; Royle et al., 2013; Yamawaki et al., 2015).  These specific 
and global cerebrovascular pathologies are implicated not only in Executive Function, 
but decline in various domains of function including Global performance, Processing 
Speed, Visual-Spatial Reasoning, and Memory (Prins et al., 2005) in addition to risk for 
the development of late-life depression  (Firbank et al., 2004; Godin et al., 2008; 
Herrmann, Le Masurier, & Ebmeier, 2007; van Sloten et al., 2015). 
4.8 Limitations of the Current Study 
 The limitations of the current study should be noted:  (a)  Neither depressive 
symptoms nor cognitive function were manipulated, limiting our ability to establish 
causality.  (b)  Individuals who were not available at wave 7 had higher depressive 
symptoms levels and tHcy, lower cognitive performance, and higher incidence of 
diabetes mellitus, and previous depression diagnosis requiring treatment.  This may 
have diminished our ability to examine the full range of the associations of CVD-RF’s, 
cognitive performance, and depressive symptoms.  However, this is a common issue in 
longitudinal studies and it is more likely that our results are a conservative estimate of 
the strength of these associations among a health sample.  (c)  Depressive symptoms 
were determined by self-report rather than by structured interview.  Although this is 
common in depression literature, it is possible that the inclusion of a structured interview 
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in addition to self-report may have increased the predictive value of symptoms of 
depression for clinical outcomes (Uher et al., 2012).  (d)  We did not have a sufficiently 
large enough sample to determine the incremental risks associated with having two 
APOE-E4 alleles compared with just one APOE-E4 allele.  (e)  This present study was 
limited to a two-wave 5-year analysis as measurement of tHcy was not available before 
wave 6 of the MSLS.  This limited our ability to study possibly non-linear associations 
over time.  (f)  Our sample was highly educated, which limited our ability to examine 
education as a potentially protective factor and modifier of CVD-RF’s on symptoms of 
depression.  (g)  In analyzing the associations of cognitive performance and a broad 
array of depressive symptoms, we may have diminished our ability to determine the 
specificity of the associations of symptom with Executive Function.  (h)  Our measure of 
Executive Function included several subtests included in other MSLS fluid reasoning 
composites and is not a pure measure of Executive Function.  As such, it is difficult to 
determine if our generalized findings are due to a true lack of differentiation between 
Executive Function and other measures of Fluid Reasoning. 
4.9 Strengths of the Current Study 
 This study has several strengths:  (a)  To our knowledge, this is the longest 
duration cross-lagged panel design analysis of executive function and depressive 
symptoms.  (b)  This is the also the first study to observe the reciprocal associations of 
depressive symptoms and cognitive function across a wide range of cognitive abilities, 
allowing us to assess the relative specificity and strength of associations of Executive 
Function and symptoms of depression compared with other domains of cognitive 
function.  (c)  Our measure of Executive Function and other domains of cognitive 
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function were composed of several subtests and were validated from previous factor 
analyses on the MSLS battery (Elias et al., 2006).  (d)  The current study adjusted for 
several demographic and CVD-RF variables and we were able to account for previous 
depression diagnosis.  (e)  Cognitive performance and depressive symptoms were 
measured continuously, increasing our ability to observe subtle variations in function.  
(f)  This is the first longitudinal analysis to consider the conditional mediation effect of 
homocysteine (moderated by age and APOE-E4 status) on depressive symptoms 
through Executive function and other domains of cognitive function.  (g)  Johnson-
Neyman analyses conducted as part of this study allowed us to analyze the continuous 
moderating effect of age on the associations of homocysteine and changes in 
symptoms of depression rather than relying on arbitrary cut points.  (h) In preliminary 
analysis, we were able to determine that prior depression diagnosis requiring treatment 
did not affect current levels of cognitive performance, extending the scope of our 
unidirectional CLPD findings. 
4.10 Future Directions 
 This longitudinal study extends the vascular depression hypothesis literature in 
showing that those with lower cognitive performance and poor vascular profiles are at 
an increased risk for symptoms of depression.  Additionally, we observed increased 
depressive symptoms among younger and middle-aged APOE-E4 carriers as a function 
of tHcy, while this risk was delayed until later adulthood for non-carriers.  Though the 
results of this study and others represent a burgeoning evidence base for the validity of 
the vascular depression hypothesis, more research is needed to extend these findings. 
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 First, many clinical profiles of vascular depression among older adults include 
gait impairment/slowing.  Many studies have shown that impaired gait function/speed 
and falls among older adults (associated with Executive Function) may be a behavioral 
marker for cerebrovascular insult (Amboni, Barone, & Hausdorff, 2013; Elias, Dore, 
Davey, Robbins, & Elias, 2010; Pinheiro et al., 2014; Rubenstein, 2006).  Although we 
did have behavioral gait speed tests available in wave 6 and wave 7, dual task 
paradigms (e.g., walking and verbal call and response) have been shown to have 
consistently stronger associations with cognitive function and aspects of Executive 
Function (i.e., attention, inhibition, working memory; Amboni et al., 2013; Holtzer, Wang, 
& Verghese, 2012).  Additionally, a recent randomized clinical trial has shown that older 
adults enrolled into a 12-week aerobic exercise group experience increases in 
Executive Function task performance and in addition to gait speed compared with a 
control group (Falbo, Condello, Capranica, Forte, & Pesce, 2016).  Future clinical trials 
need to be conducted to determine whether these increases in dual task performance 
as a function of aerobic exercise may also predict improvements in symptoms of 
depression.  A study of this design would support prior trials which have found aerobic 
exercise to be an effective treatment for depressive symptoms among both younger and 
older adults (Duman, Schlesinger, Russell, & Duman, 2008; Mura & Carta, 2013; 
Strawbridge, Deleger, Roberts, & Kaplan, 2002). 
 Second, it is possible that the associations of depressive symptoms, cognitive 
function, and CVD-RF’s are non-linear.  As such, these associations may have been 
masked or attenuated by the relatively healthy profile of our community sample.  Prior 
MSLS studies have shown that the cognitive risks associated with APOE-E4 genotype 
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are most robust in the presence of diagnosed CVD (i.e., diabetes; Dore, Elias, Robbins, 
Elias, & Nagy, 2009).  Additionally, the associations between CVD-RF’s and symptoms 
of depression may increase in strength as individuals approach resultant physical 
disability and inability to carry out activities of daily living.  Although high levels of 
depressive symptoms increase risk for dependence and disengagement from leisure 
activities for older adults, it is quite possible that institutional living itself may increase 
risk for depressive symptoms and physical disability (McDougall et al., 2007).  
Longitudinal studies are needed to determine the strength and directionality of 
associations of institutional transition, CVD progression and symptoms of depression.  
 Third, the focus of this study was on the longitudinal associations of cognitive 
performance and a broad range of depressive symptoms.  As mentioned earlier, this 
may have reduced our ability to determine the specificity of the relationships between 
subsets of symptoms and Executive Function.  Although we found that Executive 
Function was broadly associated with symptoms of depression, exploring the 
bidirectional associations of Executive Function with items relating to psychomotor 
retardation, apathy, and loss of energy may reveal a more central role of Executive 
Function in the development of depressive symptoms.  Another path to exploring the 
vascular depression subtype may be in conducting latent class analyses with subset 
measures of depressive symptoms and Executive Function performance.  Four factor 
structures have been observed in both the ZDI and CES-D and it is possible that the 
somatic/psychomotor retardation (CES-D and ZDI) and cognitive (ZDI) elements 
identified by previous factor analyses (Edwards, Cheavens, Heiy, & Cukrowicz, 2010; 
Romera, Delgado-Cohen, Perez, Caballero, & Gilaberte, 2008) may reveal specific 
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associations with Executive Function.  At this time, though a specific behavioral clinical 
profile of the vascular depression subtype has yet to be fully established (Aizenstein et 
al., 2016). 
 Lastly, the though our expanded measure of Executive Function was a significant 
predictor of changes in depressive symptoms, the distinctions between what constitutes 
an Executive Function vs. a fluid ability is unclear given their conceptual and statistical  
overlaps (see Section 4.6).  This in turn makes the incremental value of Executive 
Function over other related tests of fluid ability unclear with respect to predicting 
changes in depressive symptoms.  These distinctions may be possible to determine in 
future analyses after observing the strength of associations of Executive Function and 
depressive symptoms after adjustment for general fluid ability.  It is possible that after 
adjusting for fluid ability, there are no unique associations between depressive 
symptoms and Executive Function as we have defined it in this study. 
4.11 Implications for Clinical Practice 
 The results of this study have direct implications for clinical practice.  As the 
percentage of U.S adults in middle and older adulthood increases, more individuals will 
be at risk for cognitive decline and reduction of activities of daily living through 
cerebrovascular insult.  Our analyses in Tables 3.3 and 3.5 indicate that every 1-
standard deviation decrease in Executive Function corresponds with an approximate 
0.15-standard deviation higher Zung Depression Inventory score and 0.10-standard 
deviation increase in symptom levels over a 5-year period.  Although on the individual 
level, these effects are relatively modest, on the population level even modest 
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reductions of the risks associated with depressive symptoms have important 
epidemiological implications. 
Thus far, short-term clinical trials have been ineffective in reducing cognitive 
decline by way of tHcy-lowering diets with supplementation of B-vitamins among older 
adults, though trials of ≥ 3 years have shown to be effective in reducing stroke events 
(Clarke et al., 2014; Ji et al., 2013; Smith, 2008).  It is possible that by later adulthood, 
the benefits of supplementation on cognitive health by reducing tHcy may have 
diminishing returns as tHcy-related cerebrovascular pathology may be cumulative over 
the adult lifespan.  Future long-term clinical trials are needed with younger populations 
of adults to determine if tHcy reduction at earlier stages of life may be an effective 
preventative measure for reducing cognitive decline. 
Although the literature for B-vitamin supplementation for depressive symptoms 
reduction is scarce, early evidence is promising.  A Cochrane review of three 
randomized clinical trials (treatment 2 – 6 months duration) has shown B-vitamin 
supplementation among folate-deficient adults may be effective in further reducing 
depressive symptoms in combination with psychotropic medication (i.e., trazodone and 
fluoxetine).  However, it is unclear whether folate supplementation may be a viable 
substitute for psychotropic medications or if folate deficiency is a necessary condition 
for symptom improvement (M. J. Taylor, Carney, Goodwin, & Geddes, 2004).  It also 
remains to be seen whether the effects of these short-term folate supplementation trials 
were dependent upon reducing tHcy or CVD-RF profile.  It is also entirely possible that 
benefits of folate supplementation on depressive symptoms reduction are a result of 
tHcy’s conversion to S-adenosyl-methionine which regulates serotonin metabolism 
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(Ganguly & Alam, 2015; Refsum et al., 2004).  Long-term clinical trials are needed to 
determine the specific mechanisms of B-vitamin supplementation on depressive 
symptoms. 
Although supplementation trials have produced somewhat mixed results, 
increasing exercise and physical activity has been shown to not only be an effective 
preventive measure among healthy patients in maintenance of cognitive health and 
emotion regulation, but also as a treatment for clinical levels of cognitive impairment 
and symptoms of depression (Churchill et al., 2002; Mura & Carta, 2013).  Higher levels 
of physical activity may also prevent all-cause dementia independent of APOE-E4 
status (Podewils et al., 2005).  Regular aerobic activity has been associated with lower 
tHcy in addition to improvements among several clinical markers of cerebrovascular 
health including lower LDL, triglycerides, blood pressure, and higher HDL, glucose 
sensitivity, cerebral blood flow, and levels of brain-derived neurotropic factor (Crichton 
et al., 2014; Duman et al., 2008; Okura et al., 2006; Yoshida et al., 2010).  Lastly, 
inclusion of self-report items about physical activity and exercise to primary care 
questionnaires may increase the predictive value of Framingham Risk Scores in 
determining 10-year risk of CHD (Arsenault et al., 2010).  Although the exact 
mechanisms for the cognitive/affective benefits of regular physical activity and aerobic 
exercise may be many-fold and unclear at this time, the possibility of reducing the social 
burdens associated of any or all of these risks has far-reaching public health 
implications. 
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APPENDIX A 
Zung Depression Inventory 
Table A1 List of Zung Depression Inventory Items 
  
Number Item Reverse-Scored 
1. I feel down-hearted and blue  
2. Morning is when I feel the best X 
3. I have crying spells or feel like it  
4. I have trouble sleeping at night  
5. I eat as much as I used to X 
6. I still enjoy sex X 
7. I notice that I am losing weight  
8. I have trouble with constipation  
9. My heart beats faster than usual  
10. I get tired for no reason  
11. My mind is as clear as it used to be X 
12. I find is easy to do the things I used to X 
13. I am restless and can’t keep still  
14 I feel hopeful about the future X 
15. I am more irritable than usual  
16. I find it easy to make decisions X 
17. I feel that I am useful and needed X 
18. My life is pretty full X 
19. 
I feel that others would be better off if I 
were dead 
 
20. I still enjoy the things I used to X 
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APPENDIX B 
 Framingham Risk Score Weights 
Table B1. Framingham Risk Score for Men 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Desk reference: National Heart Lung, and Blood Institute  
http://www.ccs.ca/images/Guidelines/Tools_and_Calculators_En/Lipids_Gui_2012_FRS_BW_E
N.pdf 
 
 
 
Age Points 
 
Total 
Cholesterol 
Points  
 
Point 
Total 
10-Year 
Risk 
20-34 0  <160 0   ≤ -3 <1% 
35-39 2  160-199 1   -2 1.1% 
40-44 5  200-239 2   -1 1.4% 
45-49 6  240-279 3   0 1.6% 
50-54 8  280+ 4   1 1.9% 
55-59 10      2 2.3% 
60-64 11 
 
Systolic BP 
If 
Untreated 
If 
Treated  
3 2.8% 
65-69 12  <120 -2 0  4 3.3% 
70-74 14  120-129 0 2  5 3.9% 
75-79 15  130-139 1 3  6 4.7% 
   140-149 2 4  7 5.6% 
   150-159 2 4  8 6.7% 
   160+ 3 5  9 7.9% 
       10 9.4% 
Smoking 
Status  
Points   HDL Points 
 
11 11.2% 
Nonsmoker 0   60+ -2 
 
12 13.3% 
Smoker 4   50-59 -1  13 15.6% 
    40-49 0  14 18.4% 
Diabetes 
Status  
Points   35-44 1 
 
15 21.6% 
Diabetic 0 
  
≤34 2 
 
16 25.3% 
Non-
Diabetic 
3 
  
  
 
17 
 
29.4% 
  
  
  
 
18  or 
more 
> 30% 
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Table B2. Framingham Risk Score for Women 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Desk reference: National Heart Lung, and Blood Institute  
http://www.ccs.ca/images/Guidelines/Tools_and_Calculators_En/Lipids_Gui_2012_FRS_BW_E
N.pdf
Age Points 
 
Total 
Cholesterol 
Points  
 
Point 
Total 
10-Year 
Risk 
20-34 0  <160 0   ≤ -3 <1% 
35-39 2  160-199 1   -2 <1% 
40-44 4  200-239 3   -1 1.0% 
45-49 5  240-279 4   0 1.2% 
50-54 7  280+ 5   1 1.5% 
55-59 8      2 1.7% 
60-64 9 
 
Systolic BP 
If 
Untreated 
If 
Treated  
3 2.0% 
65-69 10  <120 -3 -1  4 2.4% 
70-74 11  120-129 0 2  5 2.8% 
75-79 12  130-139 1 3  6 3.3% 
   140-149 2 5  7 3.9% 
   150-159 4 6  8 4.5% 
   160+ 5 7  9 5.3% 
       10 6.3% 
Smoking 
Status  
Points   HDL Points 
 
11 7.3% 
Nonsmoker 0   60+ -2 
 
12 8.6% 
Smoker 4   50-59 -1  13 10.0% 
    40-49 0  14 11.7% 
Diabetes 
Status  
Points   35-44 1 
 
15 13.7% 
Diabetic 0 
  
≤34 2 
 
16 15.9% 
Non-
Diabetic 
3 
  
  
 
17 
 
18.5% 
  
  
  
 
18   21.5% 
  
  
  
 
19 24.8% 
  
  
  
 
20 27.5% 
  
  
  
 
21 or 
more 
> 30% 
  
 111 
 
APPENDIX C  
Theoretically Relevant Covariates 
Table C1. Cross-Sectional and Prospective Studies of Homocysteine and Symptoms of Depression 
 
Authors, date Design Age, 
Gender 
Covariates Results 
(Gu et al., 
2012) 
cross-
sectional 
20-90y, M/F age, sex, BMI, exercise, education, smoking, antidepressant use, creatinine level, 
alcohol use, and chronic medical conditions 
high Hcy predicted higher 
likelihood for elevated 
depressive symptoms 
(Tiemeier et 
al., 2002b) 
cross-
sectional 
≥55y, M/F age, sex, cardiovascular disease, and functional disability high Hcy associated with  
elevated depressive 
symptoms/Dx., but not after 
adjustment for functional 
disability and CVD  
(Ng, Feng et 
al., 2009) 
cross-
sectional 
≥55y, M/F  unadjusted and adjusted for age, housing size, education, social network and 
support, smoking, alcohol, underweight, obesity, antidepressant use, depression-
inducing drugs, number of medical comorbidities, disability, unintended weight 
gain/loss, supplements, anemia, albumin, and creatinine 
high Hcy unrelated to 
elevated depressive 
symptoms. 
(Nanri et al., 
2010) 
cross-
sectional 
21-67y, M/F age, site, job position, marital status, occupational physical activity, leisure-time 
physical activity, smoking and alcohol use 
high Hcy associated with 
elevated depressive 
symptoms among men 
(trend  p = .06), but not 
among women 
(Almeida et 
al., 2008) 
cross-
sectional 
≥65y, M age, education, living arrangements, smoking, alcohol use, physical activity, and 
number of medical comorbidities  
high Hcy associated with 
elevated depressive 
symptoms 
(Tolmunen et 
al., 2004) 
cross-
sectional/4.0-
year incident 
46-64, M month of study, ischemic heart disease, smoking, alcohol use, marital status, 
education, and socioeconomic status (secondary exclusion of CVD) 
baseline Hcy associated 
with baseline and incident 
elevations in depressive 
symptoms 
(Forti et al., 
2010) 
prospective, 
3.9-year 
follow-up 
≥65y, M/F Exclusion control for high depressive symptoms and adjustment for education, 
CVD, hypertension, stroke, diabetes, chronic pulmonary disease, and cancer, 
ADL disability 
 
highest homocysteine 
tertile associated with 
incident depression among 
women, but not in men 
(Kim et al., 
2008) 
prospective, 
2.4-year 
follow-up 
≥65y, M/F age, sex, education, MMSE, disability, smoking, alcohol, sedentary status, 
vascular risk score, serum creatinine  
baseline and increase in 
Hcy level associated with 
incident depression at 
follow-up 
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Table C2. Cross-Sectional and Prospective studies of Homocysteine and Cognitive function 
Authors, date Design Age, 
Gender 
Covariates Results 
(Polito et al., 
2016) 
cross-
sectional 
72-77y, M/F
  
age, sex, education, CVD, stroke, diabetes, high cholesterol, folic acid, systolic 
BP, APOE-ε4/ MTHFR, 5,10 methylenetetrahydrofolate reductase genotype 
Hcy and APOE-ε4 genotype 
inversely associated with 
executive function, but not 
memory 
(Moorthy et 
al., 2012) 
cross-
sectional 
45-103y age, sex, ethnicity, and education as well as Apo-ε4 genotype, plasma folate, 
plasma B-12 and B-6, kidney function, and presence of diabetes and 
hypertension 
low plasma B-vitamins and 
APOE-ε4 genotype inversely 
associated with MMSE score 
and positively associated 
with depressive symptoms 
(Elias et al., 
2005) 
cross-
sectional 
40-82 Framingham Stroke risk profile (age, systolic blood pressure, antihypertensive 
medication, diabetes, cigarette smoking status, cardiovascular disease, left 
ventricular hypertrophy, and atrial fibrillation), diabetes, creatinine, total 
cholesterol, BMI, alcohol intake, coffee intake, APOE-ε4 genotype, plasma B-12, 
B9 and B6 
significant interactions 
between age and Hcy.  
Associations were found 
between higher Hcy among 
adults ≥60y and reduced 
global cognitive performance 
(Elias et al., 
2008) 
cross-
sectional 
 age, sex, education, CVD, plasma B-12 and B-6  Hcy inversely associated 
with global cognitive 
performance, MMSE, 
working memory, trend for 
similarities. Significant 
interaction of APOE-ε4 
status on performance. 
(Bonetti, 
Brombo, 
Magon, & 
Zuliani, 2015) 
cross-
sectional 
≥65y, M/F age, sex, education, stroke history, cerebral atrophy (cerebral tomography), and 
plasma B-12 
hyperhomocysteinemia 
associated with highest risk 
for dementia Dx. and 
functional impairment. 
(Feng, Ng, 
Chuah, Niti, & 
Kua, 2006) 
cross-
sectional 
≥65y, M/F age, sex, and number of years of education, cigarette smoking, alcohol 
consumption, BMI, total cholesterol, hypertension, diabetes, 
cardiovascular disease, creatinine, depressive symptoms, plasma B-9 and B-12 
higher Hcy was inversely 
associated with processing 
speed and constructional 
ability (Block Design) 
(Nurk et al., 
2005) 
prospective, 
6-year 
follow-up 
 
65-67y, M/F 
 
sex, education, CVD, depression, baseline tHcy, and APOE-ε4 genotype increased Hcy was 
associated with lower 
episodic memory 
performance  
(Zylberstein et 
al., 2011) 
Prospective, 
22-year 
follow-up 
38-60, F age, education, BMI, cholesterol, triglycerides, systolic and diastolic BP, smoking, 
creatinine, and plasma B12. 
highest tertile Hcy 
associated with higher risk 
for dementia and AD 
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APPENDIX D  
Cross-Lagged Panel Analyses of other Cognitive Domains 
Figure D1. Cross-Lagged Panel Analysis for Working Memory 
 
***p<.001, **p<.01, *p<.05 +p<.10 
ST = Working Memory 
ZDI = Zung Depression Inventory 
 
Fit Indices 
RMSE = 0.060 
χ2(70) = 248.316, p < .001 
χ2/df = 3.547 
CFI = 0.954 
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Figure D2. Cross-Lagged Panel Analysis for Global composite 
 
***p<.001, **p<.01, *p<.05 +p<.10 
ST = Scanning and Tracking 
ZDI = Zung Depression Inventory 
 
Fit Indices 
RMSE = 0.077 
χ2(882) = 4648.440, p < .001 
χ2/df = 5.270 
CFI = 0.816
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Figure D3. Cross-Lagged Panel Analysis for Visual-Spatial Organization and Memory 
 
***p<.001, **p<.01, *p<.05 +p<.10 
VSOM = Visual-Spatial Organization and Memory 
ZDI = Zung Depression Inventory 
 
Fit Indices 
RMSE = 0.066 
χ2(138) = 573.539, p < .001 
χ2/df = 4.156 
CFI = 0.940
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Figure D4. Cross-Lagged Panel Analysis for Scanning and Tracking 
 
***p<.001, **p<.01, *p<.05 +p<.10 
ST = Scanning and Tracking 
ZDI = Zung Depression Inventory 
 
Fit Indices 
RMSE = 0.044 
χ2(70) = 167.777, p < .001 
χ2/df = 2.397 
CFI = 0.984 
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Figure D5. Cross-Lagged Panel Analysis for Verbal Episodic Memory 
 
***p<.001, **p<.01, *p<.05 +p<.10 
VEM = Verbal Episodic Memory 
ZDI = Zung Depression Inventory 
 
Fit Indices 
RMSE = 0.076 
χ2(42) = 216.637, p < .001 
χ2/df = 5.158 
CFI = 0.96
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